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Cocaine sensitization is associated with cocaine-induced hyperexcitability of 
pyramidal projection neurons within the medial prefrontal cortex (mPFC). Such 
hyperexcitability presumably results in increased glutamatergic input to reward-affiliated 
brain regions such as the ventral tegemental area (VTA) and nucleus accumbens (NAc), 
consequently facilitating drug-seeking behavior. Metabotropic glutamate receptor 5 
(mGluR5) has been implicated in cocaine addiction and demonstrated to increase 
neuronal excitability, therefore, the aim of the present study was to investigate the effect 
of intra-mPFC mGluR5 manipulation on behavioral and neurochemical sensitization and 
drug-seeking. Bilateral cannulae were implanted into the mPFC of male Sprague-Dawley 
rats and mGluR5 antagonist MTEP (15 nmol/side) or saline was microinjected into the 
region five minutes prior to a challenge cocaine injection. Our data showed that intra-
mPFC mGluR5 blockade via MTEP prevented late, but not early, behavioral 
sensitization. Further, intra-mPFC mGluR5 activation via DHPG (30 uM) increased 
mPFC and NAc glutamate levels in sensitized animals during early and late withdrawal, 
respectively. Finally, we observed a nonsignificant trend toward an MTEP-induced 
reduction in drug-seeking following the presentation of a cocaine-associated cue in 
animals that had been trained to self-administer cocaine. Taken together, our data suggest 
mPFC mGluR5 plays a role in cocaine addiction, possibly through the modulation of 
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Chapter 1. Introduction 
 
 
History and Use of Cocaine 
 
Cocaine was first isolated by the German chemist Albert Niemann in 1855, 
however, archeological evidence suggests dried leaves of the Erythroxylon coca shrub 
from which cocaine derives have been used for recreational and medicinal purposes by 
indigenous South Americans as far back as 3000 BC (Boghdadi and Henning, 1997; 
Johanson and Fischman, 1989; Warner, 1993). Cocaine gained popularity in Europe and 
the United States in the late nineteenth century, and the drug became available in a wide 
variety of products such as cigarettes, crystals, liquors, and the popular beverage Coca 
Cola (Boghdadi and Henning, 1997; Das, 1993; Johanson and Fischman, 1989). Cocaine 
was also added to a variety of therapeutic concoctions such as toothache, headache, and 
stomach remedies (Johanson and Fischman, 1989).  
 
Cocaine use in the United States came to a slow halt following the Harrison 
Narcotic Act of 1914 (Boghdadi and Henning, 1997; Das and Laddu, 1993), making 
cocaine far less accessible and tarnishing its image as a safe and useful substance. Further 
dissuasion from cocaine use stemmed from increased public suspicion regarding its 
toxicity (Johanson and Fischman, 1989). Because cocaine was present in such a wide 
range of consumer products and medicines, there was great opportunity for adverse 
effects to manifest and people were becoming skeptical of its benignity. Cocaine 
remained largely absent from American popular culture until its resurgence in the late 
seventies, which was augmented in part by the advent of a form of cocaine that could be 
smoked (“crack”) (Warner, 1993).  
 
While cocaine use has since declined slightly from its peak in the early eighties, 
the National Survey on Drug Use and Health (NSDUH) estimates 1.9 million current 
users in 2008, with 18-25 year olds being more likely to use than any other age group. 
The 2008 NSDUH additionally suggests that 1.4 million Americans were dependent on 
some form of cocaine, as determined by met Diagnostic and Statistical Manual of Mental 
Disorders criteria. The 2008 Drug Abuse Warning Network report revealed that cocaine 
was responsible for a fourth of the two million drug-related emergency room visits that 
occurred that year. Finally, relapse rates hover around 60% for cocaine and 85% for 
crack, suggesting that current treatments warrant some improvement (Statistical data 
from National Institute of Drug Abuse website: www.nida.org).  
 
 
Chemistry and Forms of Cocaine 
 
Cocaine is an alkaloid that derives from the leaves of the Erythroxylon shrub, or 
coca plant, which grows in the Andes mountains of South America (Johanson and 
Fischman, 1989). Cocaine accounts for 1% of the weight of coca leaves and chewing the 
leaves has been a common form of administration for millennia. However, low 
gastrointestinal absorption and the relatively low concentration of cocaine in the leaves 
 2
results in noticeable, but comparably minimal, effects (Warner, 1993). By contrast, when 
combined with hydrochloric acid (cocaine hydrochloride), cocaine becomes a water-
soluble salt that can consequently be injected or nasally insufflated, resulting in far 
greater drug absorption. Cocaine hydrochloride may also be dissolved in water, mixed 
with sodium bicarbonate, and heated, resulting in a solid substance that can be smoked, 
most commonly in a glass pipe or cigarette (Khalsa et al., 1992). Heating this form of 
cocaine produces a popping sound that earned it the street name “crack”. Due to its lower 
cost and greater accessibility, crack has surpassed traditional cocaine in popularity and is 
now the most commonly used form of the drug (Boghdadi and Henning, 1997). 
 
 
Pharmacokinetics and Metabolism of Cocaine 
 
Cocaine can be smoked, injected, or nasally insufflated. The drug reaches the 
cerebral circulation in 6-8 seconds when smoked, 1-2 minutes when intravenously 
injected, and 3-5 minutes when absorbed through the nasal mucous membranes 
(Johanson and Fischman, 1989; Warner, 1993). Peak plasma levels are higher and 
achieved more quickly when cocaine is smoked or injected than when it is snorted; 
seconds for the former and up to an hour for the latter (Johanson and Fischman, 1989) 
(Boghdadi and Henning, 1997). The delay is due, in part, to cocaine’s vasoconstrictive 
action on the nasal mucosa that slows the drug’s absorption (Warner, 1993). However, 
this impediment also results in the prolonged presence of cocaine in the plasma, 
sometimes up to 6 hours, while subjects who intravenously administered the drug 
reported a significant decrease in the effects just 40 minutes after the injection (Javaid et 
al., 1978).  
 
The plasma half-life of cocaine ranges from 30-90 minutes (Javaid et al., 1983) 
(Warner, 1993), however, its clearance from other tissues can be substantially slower 
(Johanson and Fischman, 1989). Approximately 95% of cocaine is metabolized into 
benzoylecgonine, ecgonine methyl ester, or norcocaine (Warner, 1993).  The vast 
majority (80-90%) of cocaine is metabolized into ecgonine methyl ester and 
benzoylecgonine via enzymatic and nonenzymatic hydrolysis, respectively (Johanson and 
Fischman, 1989; Warner, 1993). The plasma half-lives of benzoylecgonine and ecgonine 
methyl ester are four and seven hours, respectively, however they can remain in the urine 
for up to two weeks. Benzoylecgonine urine concentrations are 50-100 times higher than 
those of cocaine or ecgonine methyl ester, so the metabolite is consequently targeted in 
cocaine screening tests, which most commonly employ gas chromatography/ mass 
spectrometry (Boghdadi and Henning, 1997; Warner, 1993). A small amount of cocaine 
is metabolized into norcocaine via N-demethylation in the liver (Warner, 1993). This 
metabolite can be potentially toxic to individuals with cholinesterase deficiencies, 







Pharmacodynamics of Cocaine 
 
The two primary pharmacologic actions of cocaine are the blockade of sodium 
channels and the prevention of monoamine reuptake (Boghdadi and Henning, 1997). The 
blockade of fast sodium channels in neuronal and cardiac cells ultimately attenuates 
depolarization and action potential conduction (Benowitz, 1993; Boghdadi and Henning, 
1997). This may lead to arrhythmia, which is associated with stroke and sudden death 
(Benchimol et al., 1978). Myocardial infarction can also be induced through cocaine’s 
blockade of norepinephrine reuptake, which can lead to increased heart rate and blood 
pressure. Cocaine’s sodium channel occlusion has resulted in its use as a topical 
anesthetic. In the past, it was used most often in ophthalmological settings, but was later 
found to induce corneal epithelial sloughing (Johanson and Fischman, 1989). Presently, it 
is utilized almost exclusively as an anesthetic during respiratory tract surgeries in a 4% 
concentration with very few adverse effects (Johanson and Fischman, 1989). 
 
Virtually all drugs of abuse increase dopaminergic transmission in reward-
associated brain regions, such as the ventral tegmental area (VTA) and nucleus 
accumbens (NAc). Cocaine prevents monoamine reuptake by blocking transporters on 
presynaptic terminals, resulting in increases of a given neurotransmitter in the synaptic 
cleft (Benowitz, 1993). Since brain areas such as the VTA and NAc have a high 
concentration of dopamine transporters, cocaine increases dopamine in these regions and 
it is this action that accounts for its addictive potential (Fleming et al., 1990).  
 
 
Medical Consequences of Cocaine Use 
 
Both sporadic and chronic cocaine use can lead to wide range of health conditions 
(Boghdadi and Henning, 1997). In the central nervous system, strokes (Levine et al., 
1991) seizures (Dhuna et al., 1991), and movement disorders (Hegarty et al., 1991) can 
occur in first-time users, as well as seasoned addicts who have never experienced any 
cocaine-related complications in the past. Cocaine-induced cardiac problems are 
numerous, including arrhythmia (Benchimol et al., 1978), endocarditis (Chambers et al., 
1987), myocardial infarction (Isner et al., 1986), cardiomyopathy (Om et al., 1992), and 
ruptured aorta (Barth et al., 1986).  
 
Pulmonary consequences can occur following any route of cocaine 
administration, but are most likely to result from smoking crack cocaine (Boghdadi and 
Henning, 1997). Respiratory complications include, but are not limited to, inhalation 
injuries (Boghdadi and Henning, 1997), vascular abrasions and bleeding (Bailey et al., 
1994) (Murray et al., 1988), and edema (Hoffman and Goodman, 1989).  
 
Gastrointestinal complications primarily result from cocaine’s vasoconstrictive 
actions on gastric arteries  (Boghdadi and Henning, 1997) and comprise gastroduodenal 
ulcers (Kram et al., 1992), intestinal tears Freudenberger 1990 (Freudenberger et al., 
1990), and colitis (Brown et al., 1994).  
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In the kidney, cocaine use can result in acute rhabdomyolysis, renal infarction, 
and acute renal failure (Boghdadi and Henning, 1997; Merigian and Roberts, 1987)  
(Kramer and Turner, 1993). Rhabdomyolysis, a condition whereby skeletal muscle 
components such as myoglobin leak into the bloodstream and compromise renal function, 
accounts for one fourth of cocaine-related emergency room cases (Boghdadi and 
Henning, 1997). The vasoconstrictive action of cocaine and resultant muscle ischemia is 
thought to be primarily responsible for this condition, however, excessive amounts of 
cocaine may also induce direct muscle deterioration (Boghdadi and Henning, 1997; 
Nolte, 1991). 
 
Since cocaine easily and rapidly crosses the placenta, use during pregnancy can 
have tragic effects on the fetus. These complications include spontaneous abortion 
(Chasnoff et al., 1985), stillbirth, placenta previa (Chasnoff et al., 1989), congenitial 
abnormalities (Handler et al., 1991), and premature birth (Handler et al., 1991). Once 
born, the neonate may suffer seizures, tachycardia, and cocaine withdrawal (Boghdadi 
and Henning, 1997; Burkett et al., 1990). 
 
Cocaine possesses intense euphorigenic properties due to its ability to increase 
dopamine in the reward circuit (discussed in greater detail later), but it also can result in 
less pleasurable psychiatric conditions such as depression, agitation, psychosis, delirium 
and delusions. In some cases, these altered psychiatric states can have devastating 
consequences like accidents, suicide and homicide (Warner, 1993). Due to cocaine-
induced impairments in judgment, users are also at risk for contracting sexually 
transmitted diseases such as HIV. HIV transmission, along with hepatitis, is also 
increased in intravenous cocaine users. 
 
 
Euphorogenic Effects of Cocaine 
 
As previously discussed, one of cocaine’s primary actions is monoamine 
transporter blockade, which leads to increases in monamines (dopamine, norepinephrine, 
and serotonin) in the synaptic cleft. While cocaine binds with five and three times greater 
affinity to the serotonin and norepinephrine transporter, respectively, a large body of 
evidence suggests the rewarding element of cocaine use derives from the drug’s effects 
on the dopamine transporter (White and Kalivas, 1998). While data imply cocaine’s 
action at the serotonin and norepinephrine transporters plays a significant role in setting 
the stage for addiction (Steketee, 2003; White and Kalivas, 1998), experiments in which 
these two transporter types were manipulated have not shown a relationship between their 
function and euphoria or drug-seeking behavior (White and Kalivas 1998). By contrast, 
dopamine transporter knockout mice do not exhibit locomotor sensitization (discussed in 
the following section) in response to repeated cocaine (Giros et al., 1996). Furthermore, 






Animal Models of Addiction 
 
The two most widely used methods for studying addiction are the contingent and 
noncontingent models. In the noncontingent paradigm, cocaine is repeatedly administered 
to the animal by the experimenter while in contingent paradigms, the animal is trained to 
self-administer cocaine. Behavioral sensitization is the most commonly studied 
phenomenon using the noncontingent method and refers to the increase in drug-induced 
locomotor activity observed following repeated drug exposure. The majority of my 
project focuses on sensitization, so it will be discussed in greater detail in the following 
sections. In self-administration models, relapse (via reinstatement) or drug-seeking can be 
measured. In self-administration experiments, laboratory animals are trained to respond 
(lever-press, nose poke) to a cue in order to obtain an intravenous drug injection (Shaham 
et al., 2003). Generally, animals are considered to have learned the task when they are 
reliably responding at the appropriate times, however, specific goal criteria varies among 
labs and experiments. After animals have learned, they either undergo extinction training 
wherein responding only results in an intravenous saline injection, or return to their home 
cages for a certain period of time (days to weeks) before being placed back in the self-
administration chambers. In the former and more common condition, the experimenter is 
studying reinstatement; in the latter, drug-seeking is being assessed. Reinstatement, 
considered by many to be the most valid model for relapse, consists of re-exposing the 
extinguished animal to drug or presenting it with a cue previously associated with drug. 
The animal is then again placed in the self-administration chamber and its response 
activity is recorded (responses at this stage only deliver intravenous saline). The 
overarching goal of most reinstatement studies is to determine whether various 
pharmacological or environmental manipulations can reduce the risk of relapse. The goal 
of drug-seeking experiments is generally the same, but the methodology differs in that the 
animal does not learn to dissociate the self-administration chamber and the drug. The 
downside of this is that the relapse-prevention medium under scrutiny may not need to be 
as effective to produce a significant effect as it would if tested under a reinstatement 
paradigm. However, evidence suggests that neuroadaptations occur in rodents following 
extinguishment (Knackstedt et al., 2010) and such adaptations may result in a neural 
landscape that differs significantly from that of an addicted individual. Consequently, a 
relapse-prevention tool effective in one state may not generalize to another.  
  
While the self-administration paradigm is currently considered the most valid 
model in the addiction field, there has been a fair amount of debate regarding the validity 
of sensitization. Perhaps the most common qualm is skepticism about whether the neural 
underpinnings of sensitization parallel those that occur in addiction, however, a recent 
review suggests substantial overlap between the two models (Steketee and Kalivas, 
2011). Nonetheless, given the controversy, we decided to conduct a similar investigation 
of the role mPFC mGluR5 in drug-seeking using the self-administration paradigm to 
further corroborate both the role of mPFC mGluR5 in addiction as well as the relevance 





Sensitization and Addiction 
 
Behavioral sensitization to cocaine was first observed in 1932 and refers to the 
increase in locomotor activity in response to cocaine following repeated cocaine exposure 
(Steketee, 2003). Sensitization also occurs in response to other drugs of abuse, such as 
amphetamine, nicotine, alcohol, and morphine (Robinson and Becker, 1986; Steketee and 
Kalivas, 2011). The role of sensitization in addiction is presently controversial, however, 
a good deal of evidence suggests common mechanisms mediate both processes 
(Robinson and Berridge, 1993). There is also significant overlap between studies of 
sensitization (Steketee and Kalivas, 2011) and those of reinstatement, a model considered 
by many to validly depict relapse. It has additionally been shown that animals that exhibit 
a strong sensitized response to a drug are more likely to relapse in a self-administration 
paradigm (DeVries et al., 1998). Furthermore, cross-sensitization occurs between various 
drugs of abuse, indicating sensitization derives from mechanisms characteristic of a 
general addicted neural state (Steketee, 2003). Finally, both sensitization and addiction 
share the qualities of longevity and susceptibility to individual differences (Tzschentke 
and Schmidt, 2003). Addiction is a lifelong struggle and sensitization can be observed for 
at least a year following the last exposure to a drug, suggesting sensitization is a 
fundamental element of the resilient neuroadaptations that occur following repeated drug 
use. Sensitization cannot be observed in every animal that is repeatedly exposed to a 
drug, just like every individual who uses a drug will not become an addict. Factors such 
as frequency of exposure, gender, age, and genetics influence sensitization and addiction 
(Steketee and Kalivas, 2011). 
 
Sensitization is generally divided into two stages: initiation and expression. 
Initiation refers to the development of sensitization that occurs during the first few 
exposures to the drug. The VTA is believed to play a significant role in this phase, seeing 
as its inactivation prevents sensitization (Koob et al., 1981) and a number of early 
modifications occur in this region following initial drug encounters (Kauer, 2004)  
(Carlezon and Nestler, 2002; Thomas and Malenka, 2003). Expression can be further 
divided into an early and late phase. Early expression is usually considered to be between 
one and fourteen days from the last drug exposure while late expression is twenty-one 
days and beyond following the last drug exposure. The nucleus accumbens is thought to 
be the seat of lasting, drug-induced modifications that mediate the expression of 
sensitization (Steketee and Kalivas, 2011).  
 
Sensitization is typically measured through observing drug-induced locomotor 
activity. Experiments usually consist of two groups of animals: one that receives 
repeated, consecutive daily injections of drug (over x number of days; four, in our 
studies) and one that receives an equivalent amount of saline for an equivalent amount of 
time. After a certain time point following the last injection (our experiments look at 
seven, fourteen, or twenty-one days), a challenge injection of drug is administered and 
locomotor activity is measured for a certain amount of time (120 minutes in our lab). If 
sensitization has occurred, a significantly greater amount of locomotor activity in the 
drug group would be expected relative to saline controls.  
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Brain Regions that Mediate Sensitization 
 
Sensitization derives from alterations in the mesocorticolimbic (MCL), or reward, 
circuit in the brain, consisting of the VTA, NAc and medial prefrontal cortex (mPFC). 
The hippocampus, amygdala, laterodorsal tegmentum and the paraventricular nucleus are 
additionally believed to be involved in sensitization, but probably via interaction with the 
MCL circuit (Steketee and Kalivas, 2011). Dopaminergic projections from the VTA to 
the NAc are perhaps the most crucial and well-studied element of the MCL circuit, as 
they are the source of dopamine release in the NAc which, as previously mentioned, is 
necessary for a drug to be subjectively evaluated as rewarding. The mPFC sends 
glutamatergic projections to the VTA and the NAc (Sesack and Pickel, 1992), and the 
importance of these projections in the regulation of addictive behavior is beginning to 
come to light. The VTA and NAc also send reciprocal dopaminergic and GABAergic 
projections, respectively, back to the mPFC  (Oades and Halliday, 1987).  
 
Lesion studies have been a useful, albeit first-pass, method for determining the 
necessity of certain brain structures for the sensitization process. Inactivation of the VTA 
and the NAc via radiofrequency or 6-hydroxydopamine diminished the sensitized 
locomotor response to amphetamine (Koob et al., 1981), while ibotenic acid mPFC 
lesions prevented behavioral cocaine sensitization(Li et al., 1999). The VTA has been 
shown to be essential for the initiation of sensitization, while the NAc is deemed vital for 
expression. Consistent with this, the mPFC can be subdivided into several regions that 
each project predominantly to different brain structures and lesioning the mPFC area 
projecting to the VTA prevents the initiation of sensitization, while lesioning the area 
projecting to the NAc prevents expression (Pierce et al., 1998) (Steketee, 2003).  
 
 
Cellular and Neurochemical Adaptations of Sensitization 
 
A wide range of studies have demonstrated alterations in MCL brain structures 
following repeated and acute cocaine exposure. These changes are believed to underlie 
the unmanageable drug-seeking behavior observed in addicts, so an understanding of the 
nature and temporal profile of these adaptations is critical to the development of 
pharmacotherapies to treat addiction and prevent relapse. In the following sub-sections, I 
will delineate documented changes in the VTA and the NAc. Since the basis of my 
project rests on alterations in the mPFC, I will cover these in the next section. 
 
 
Alterations in the VTA 
 
At present, most noted alterations in the VTA are thought to be transient, 
functioning primarily to mediate the early stages of sensitization (White and Kalivas, 
1998). In support of this, dopamine levels in response to cocaine were found to be 
initially elevated in sensitized rats but were indistinguishable from controls by fourteen 
days post-exposure, however, behavioral sensitization could still be observed at this time 
point (Kalivas and Duffy, 1993). Additionally, repeated intra-VTA administration of the 
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dopamine re-uptake inhibitor GBR 12909 induced a sensitization to cocaine that was not 
significantly different from that elicited in animals that received repeated cocaine, 
suggesting enhanced VTA dopamine levels lead to sensitization (Cornish and Kalivas, 
2001). Some relationships between dopamine receptors and sensitization in the VTA 
have been observed, as well. Repeated intra-VTA injections of D1 receptor agonist SKF-
38393 induces cross-sensitization to a cocaine challenge in drug-naive rats (Pierce et al., 
1996). D1 receptor knock-out mice do not exhibit increased locomotor activity in 
response to acute cocaine or sensitization to a higher dose of repeated cocaine, however, 
it was ironically found that these mice displayed some (albeit nonsignificant) 
sensitization to a lower dose of repeated cocaine (Karlsson et al., 2008). Finally, it has 
been suggested that dopamine autoreceptors are less sensitive following cocaine 
sensitization (Henry and White, 1991; White and Kalivas, 1998). 
 
In addition to dopamine, elevated glutamate levels have been observed in 
sensitized rats following a challenge cocaine injection administered twenty-one days 
from the last sensitizing injection (Kalivas and Duffy, 1998). Glutamatergic transmission 
in the VTA also appears to be augmented in sensitized rats, as evidenced by an increase 
in neuronal firing following in vivo iontophoretic glutamate application (White et al., 
1995). Single-cell recording found VTA dopamine neurons to be more sensitive to 
iontophoretically administered AMPA in sensitized versus saline animals (Zhang et al., 
1997). Increased levels of GluR1 and NMDAR1 were observed in the VTA of sensitized 
rats (Fitzgerald et al., 1996) and intra-VTA injections of NMDAR antagonists block the 
development of sensitization (Kalivas and Alesdatter, 1993). Data suggest a single 
exposure to cocaine can potentiate synaptic AMPA currents on dopaminergic projection 
neurons in the VTA (Ungless et al., 2001). This potentiation was demonstrated to last for 
at least five, but not more than ten, days post-exposure, further corroborating a transient, 
but necessary, role for the VTA in sensitization. This cocaine-induced increase in VTA 
neuronal excitability was later found to depend on an inhibition of GABA-ergic synapses 
that occurs following repeated cocaine, and could be prevented by the administration of 
GABA agonist diazepam (Liu et al., 2005). 
 
Taken together, these data suggest cocaine exposure induces a short-lived 
plasticity in VTA dopaminergic output neurons that serves to increase input to target 
regions, such as the NAc and mPFC. It is assumed that this transient increase in 
dopaminergic transmission sets the stage for more lasting alterations in other reward-
associated brain structures. 
 
 
Alterations in the NAc 
 
In contrast to the VTA, cocaine-induced changes in the NAc are generally 
believed to be longer lasting and may consequently play a greater role in the 
unmanageable drug-seeking behavior observed in addiction. Several studies have 
demonstrated AMPA alterations in the NAc following repeated cocaine exposure, 
suggesting glutamatergic transmission in the NAc may play an important role in relapse. 
An increase in locomotor activity was observed following intra-NAc microinjections of 
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AMPA in sensitized animals relative to saline controls at 14 to 21 days withdrawal 
(Pierce et al., 1996). Intra-NAc AMPA injections were also found to increase drug-
seeking behavior following a 28-day withdrawal period in sensitized rats (Suto et al., 
2004). Moreover, administration of an AMPA receptor antagonist was found to prevent 
reinstatement when injected directly into the NAc (Cornish and Kalivas, 2000). Further, 
an increase in GluR1 was observed in the NAc at 21 (but not 1) days cocaine withdrawal 
in sensitized rats (Churchill et al., 1999). A later study found an increase in NMDA 
receptor subunits NR1, NR2A, and NR2B at the delayed (21 day), but not immediate (1 
day) time point (Schumann and Yaka, 2009). Finally, in NAc brain slices of sensitized 
mice, a strong, AMPA-mediated long-term potentiation was observed following an 
extended period of withdrawal, however, a single administration of cocaine rapidly 
abolished this LTP and instead induced LTD (Kourrich et al., 2007).  
 
Basal glutamate levels in the NAc are reduced following repeated cocaine (Baker 
et al., 2002), while a challenge injection of cocaine was found to increase glutamate in 
the NAc of sensitized animals relative to controls (Reid and Berger, 1996). This decrease 
in basal glutamate is hypothesized to be due, in part, to a cocaine-induced disruption in 
the function of the cysteine-glutamate anti-porter (Baker et al., 2003), which appears 
plausible given that N-acetyl-cysteine can restore glutamate levels and prevent 
reinstatement (Baker et al., 2003) and sensitization (Madayag et al., 2007). This data in 
combination with the abovementioned AMPA receptor alterations suggest repeated 
cocaine may induce a potentiated state in NAc synapses characterized by low glutamate 
levels that serves to heighten contrast between a drug-abstinent and a drug-using state, 
ultimately arming cocaine and its cues with greater influence over behavior (Steketee and 
Kalivas, 2011). 
 
Contrary to what one might expect, there does not appear to be a great deal of 
cocaine-mediated dopamine alterations in the NAc, at least not relative to glutamate 
(White and Kalivas, 1998). That said, dopamine increases in the NAc have been observed 
following repeated cocaine (Kalivas and Duffy, 1990). A recent in vivo study 
demonstrated via fast-scan cyclic voltammetry a cocaine-induced dopamine increase in 
the NAc at 7 (but not 1) days withdrawal in sensitized rats (Addy et al., 2010). An 
increased sensitivity in D1, but not D2, receptors in the NAc was observed at 7 and 30, 
but not 60, days withdrawal in sensitized rats (Henry and White, 1991).  
 
 
Involvement of the mPFC in Sensitization and Addiction 
  
The mPFC is perhaps most colloquially associated with the famous case of 
Phineas Gage, the nineteenth-century railway worker impaled through the skull by an 
iron rod during an explosion. While the injury did not leave Gage with any lasting 
impairments that were necessarily obvious to the casual observer, those who knew him 
before the accident were unanimous in attesting that he was "no longer Gage". Prior to 
the accident, Gage was reportedly careful, respectful, responsible, and business-minded--
-a demeanor that contrasted sharply with the reckless, crude and capricious disposition in 
its place following the injury. Due to Gage's irresponsibility and inability to comprehend 
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the exchange of currency, he spent the last decade of his life working for Barnum's circus 
as an exhibit before he died from epilepsy in 1860, just twelve years after the accident. 
Later examination of Gage's skull and those of other individuals who sustained similar 
injuries revealed that the iron rod had most likely damaged Gage's prefrontal cortex, a 
brain region now implicated in attention, working memory, reward processing, emotional 
regulation, decision-making, impulsivity and inhibition, self-monitoring, and reversal 
learning (Perry et al., 2011).  
 
The human prefrontal cortex can be divided into medial, lateral, and orbital 
regions (Perry et al., 2011). The medial region consists of the mPFC and anterior 
cingulate cortex (ACC), and most cortically based cocaine abuse research in humans and 
laboratory animals has focused on these regions. The lateral region of the PFC contains 
distinct dorsal and ventral areas, as well as an inferior frontal junction (Ridderinkhof et 
al., 2004). The lPFC sends and receives projections from premotor regions, which 
ultimately originate in the motor cortex. This particular connectivity enables the lPFC to 
influence behavior (Perry et al., 2011). The orbital region communicates with other areas 
of the PFC and receives a wide range of sensory input.  
 
In rodents, reciprocal connections exist between the mPFC and the NAc, VTA, 
hypothalamus, hippocampus, amygdala, and other regions of the cortex (Dalley et al., 
2004; Perry et al., 2011). The rat mPFC is generally subdivided into dorsal and ventral 
regions, with the former consisting of the precentral and anterior cingulate cortices and 
the latter encompassing the prelimbic, infralimbic, medial orbital, and ventral orbital 
regions. Unlike human mPFC, there does not appear to be a connectivity-based lPFC 
correlate in rodents (Perry et al., 2011).  
 
A growing base of human and laboratory animal studies point to a role of the 
mPFC in cocaine addiction. Imaging studies in human addicts generally show an increase 
in mPFC activity in response to or in expectation of cocaine, as well as following drug-
related cues (Goldstein and Volkow, 2011; Kufahl et al., 2008; Kufahl et al., 2005). In 
rodents, mPFC lesions induced prior to repeated cocaine exposure prevented behavioral 
sensitization (Li et al., 1999; Tzschentke and Schmidt, 1998) and cocaine injections 
administered directly into the mPFC induced reinstatement in previously trained rats 
(Park et al., 2002). As previously mentioned, obliteration of projections from the mPFC 
to the NAc and VTA abolishes the expression and initiation of sensitization, respectively. 
Taken together, these studies suggest the mPFC is essential in mediating the pathological 
neuroadaptations that follow repeated cocaine. 
 
Increasing amounts of data suggest neurochemical and electrophysiological 
alterations occur in the mPFC following repeated cocaine exposure. Cocaine-mediated 
mPFC dopamine levels are decreased during early sensitization but increased during late 
sensitization and the reverse is true for glutamate levels (Williams and Steketee, 2005) 
(Williams and Steketee, 2004). Relatedly, mPFC dopamine D2 and Group II 
metabotropic glutamate receptor (mGluR) function was found to be reduced in rats 
following repeated cocaine exposure (Beyer and Steketee, 2002; Xie and Steketee, 2009). 
Additionally, a reduction in a Group II mGluR-mediated form of mPFC long-term 
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depression (LTD) was observed in slices from rats repeatedly treated with cocaine 
(Huang et al., 2007). Repeated cocaine was shown to alter the excitability of mPFC 
pyramidal projection neurons during early and late withdrawal (Nasif et al., 2005), a 
phenomenon the authors attributed to a decrease in membrane afterhyperpolarization and 
an increase in L-type calcium channel activity (Ford et al., 2009; Hu, 2007). Together, 
these studies suggest repeated cocaine induces early and late changes in the mPFC at the 
neurotransmitter and cellular level that may ultimately alter mesolimbic transmission in a 
manner that facilitates drug-seeking.  
 
The role of the mPFC in executive function and its projections to addiction-
related regions like the VTA and NAc easily inspires the question of whether mPFC 
dysfunction contributes to the loss-of-control over drug-seeking behavior seen in cocaine 
addicts. Indeed, imaging studies have demonstrated an overall reduction in mPFC 
function in addicts that can be remedied by drug exposure (Goldstein and Volkow, 2011). 
Cocaine addicts showed a reduction in ACC activity relative to non-addicts during the 
inhibitory-control-measuring Go/no-go task that correlated with poorer performance 
(Kaufman et al., 2003). Further, cocaine addicts’ performance on the Stroop task, a 
measure of overall mPFC function, was significantly lower than that of non-addicts 
(Bolla et al., 2004) and pre-rehabilitation Stroop performance was found to predict 
treatment outcome (Brewer et al., 2008; Goldstein and Volkow, 2011). Addicts’ 
deficiencies in the Go/no-go task and associated ACC hypoactivity could be corrected via 
intravenous cocaine administration (Garavan et al., 2008). A similar rectification was 
observed in the Stroop task following oral methylphenidate, a mild stimulant and DAT 
antagonist (Goldstein et al., 2010). Cocaine addicts also appear to place less value on 
non-drug rewards than non-addicts. For example, one study assessing this found 
significantly less mPFC activation following the acquisition of a monetary reward in 
addicts relative to controls (Goldstein et al., 2007). This is consistent with the relatively 
large number of animal studies that demonstrate consistent selection of drug over non-
drug rewards following repeated cocaine exposure, even when the non-drug rewards are 
vital to the animal’s survival (Goldstein and Volkow, 2011). Taken together, this 
evidence suggests repeated cocaine exposure results in an mPFC that is generally less 
responsive to non-drug-related stimuli. If this is the case, treatments for cocaine addiction 
designed to rectify cocaine-induced adaptations in the mPFC will be markedly more 
promising than those that do not. Therefore, an understanding of the changes that occur in 
the mPFC following repeated cocaine exposure is necessary. To gain such an 
understanding, the mechanisms generating the marked polarization in mPFC excitability 
between cocaine-related and unrelated scenarios should be uncovered. Given that 
glutamate is the most pervasive and influential excitatory transmitter in the brain and 
responsible for virtually all forms of plasticity, cocaine-induced alterations in the mPFC 








mPFC mGluR5 and Cocaine Addiction 
 
As previously mentioned, mPFC glutamate levels are elevated in response to 
cocaine during early withdrawal but return to baseline by late sensitization (Williams and 
Steketee, 2004), suggesting that transient neurotransmitter changes may pave the way for 
more permanent receptor alterations. Also mentioned earlier, studies have demonstrated 
alterations in intrinsic pyramidal cell membrane properties (Nasif et al., 2005), ion 
channel attributes (Ford et al., 2009), intracellular signaling (Bowers et al., 2004), 
plasticity and Group II mGluR function following repeated cocaine exposure, suggesting 
that long-term aberrations in mPFC excitability may predominantly be mediated via 
changes in pyramidal projection cells. Consequently, when we set out to examine 
potential cocaine-induced alterations in the mPFC glutamate system, we wanted to focus 
on an element capable of effecting long-term changes in the cell.   
 
mGluR5 is a member of the Group I mGluR family that also includes mGluR1. 
Selectively located in corticolimbic regions, these Gq/G11-coupled receptors are 
predominantly postsynaptic in the mPFC and generally serve to increase the excitability 
of pyramidal neurons (Homayoun and Moghaddam, 2010; Kew and Kemp, 2005). There 
are three primary reasons we were interested in the role of mGluR5 in cocaine-induced 
mPFC alterations. First, mGluR5-null mice do not exhibit a sensitized locomotor 
response to repeated cocaine (Chiamulera et al., 2001) and several studies have shown 
that systemic mGluR5 antagonism prevents various facets of addiction in rodents, such as 
reinstatement and sensitization (Martin-Fardon and Weiss, 2012); (Platt et al., 2008). 
mGluR5 manipulation in reward-related brain regions has also affected addictive 
behavior in rodents. For example, NAc mGluR5 blockade prevented and mGluR5 
stimulation augmented cocaine-seeking behavior in a self-administration paradigm 
(Wang et al., 2012). Another intriguing study that selectively knocked down mGluR5 in 
D1-expressing neurons found that, while the affected mice still self-administered cocaine, 
cue-induced reinstatement was impaired, leading the authors to surmise that mGluR5 
activation on D1-expressing cells is necessary for the assignment of drug-related 
importance to previously neutral stimuli (Novak et al., 2010). 
 
Secondly, as previously mentioned, alterations in mPFC pyramidal cell 
excitability and consequent changes in communication between the mPFC and the NAc 
and VTA may contribute significantly to resilient drug-seeking behavior observed in 
addicts. mGluR5 activation in thalamic, hippocampal, and nigral slices induces excitatory 
postsynaptic potentials (EPSPs) and can lead to depolarization and increased firing 
frequency (Awad et al., 2000; Homayoun and Moghaddam, 2010). Given that mPFC 
projection neurons are hyperexcitable in response to cocaine following repeated cocaine 
exposure, increased mGluR5 activation may contribute to this excitability.  
 
Relatedly, our third reason for investigating mGluR5 is its purported modulatory 
influence on neuronal firing. One study demonstrated that in vivo mGluR5 blockade via 
antagonist MPEP in the mPFC prevented firing of roughly 50% of pyramidal neurons 
(Homayoun and Moghaddam, 2006). The authors noted that MPEP preferentially 
prevented the firing of cells that possessed a greater baseline firing level (Homayoun and 
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Moghaddam, 2010), which they attested suggests mGluR5 may greatly influence the 
overall regional output. As mentioned earlier, repeated cocaine exposure appears to result 
in an mPFC that is hypoactive in response to non-drug stimuli, but hyperactive in 
response to cocaine and its cues. That said, it is tempting to speculate that 
pharmacological mGluR5 inhibition or modulation could ultimately attenuate the 
influence of cocaine-related stimuli on drug-seeking behavior by reducing the excessive 
firing of mPFC pyramidal neurons that ensues when an addicted individual encounters 
such stimuli. Of clinical importance is the evidence suggesting mGluR5 modulation (not 
antagonism) can fine tune elements of neuronal behavior without disrupting overall 
transmission as would occur with ionotropic glutamate receptors, and such modulatory 
drugs have shown promise in attenuating drug-seeking behavior in animals (Olive, 2009). 
Consequently, further research into the role of mGluR5 in cocaine-induced neuroplastic 
changes in the mPFC could lead to safe and effective pharmacotherapies for addiction. 
 
 
Summary and Rationale 
 
A functional mPFC enables an organism to effectively evaluate its environment 
and make advantageous long-and short-term decisions. Evidence suggests repeated 
cocaine leads to lasting changes in the mPFC and it is possible that these alterations are 
responsible for addicts’ inability to regulate drug-seeking behavior. Adaptations in mPFC 
pyramidal projection neurons can result in increased and decreased output to the VTA 
and NAc in response to different types of stimuli. Given that glutamate is the most 
abundant excitatory neurotransmitter in the brain and glutamatergic transmission 
mediates the vast majority of neural plasticity, the current project focuses on the role of 
mGluR5 in cocaine-induced mPFC neuroadaptations. mGluR5-null mice do not sensitize 
to cocaine and mGluR5 antagonism has been repeatedly shown to reduce drug-seeking 
behavior in laboratory animals. Further, mGluR5 stimulation has been demonstrated to 
exert both a modulatory and an excitatory effect on the cell. Therefore, the current project 
described below focuses on the effect of mPFC mGluR5 manipulations on cocaine 
sensitization, self-administration, and neurotransmission in the mPFC, VTA and NAc. 
We hypothesize mPFC mGluR5 activation contributes to pyramidal neuronal excitability 
in sensitized animals and consequently influences behaviors and neurochemical profiles 





1) To examine the effects intra-mPFC mGluR5 manipulation on behavioral 
sensitization to cocaine 
2) To compare mPFC, VTA and NAc glutamate levels in response to intra-mPFC 
mGluR5 stimulation in sensitized and control animals 
3) To test the ability of mPFC mGluR5 antagonism to attenuate drug-seeking 
behavior in a self-administration paradigm 
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Chapter 2. Examination of a Role for Metabotropic Glutamate Receptor 5 in the 





Chronic cocaine exposure has been shown to induce enduring neuroadaptations 
that collectively result in the loss of control over drug-seeking behavior despite 
multitudinous adverse consequences (Nestler, 2005). Behavioral sensitization, the 
augmented locomotor response to cocaine following repeated exposure, has been shown 
to have predictive validity for other indicators of addiction such as reinstatement, 
possibly due to shared cocaine-induced modifications in neurocircuitry (Kalivas et al., 
1998; Robinson and Berridge, 1993; Steketee and Kalivas, 2011). The human medial 
prefrontal cortex’s (mPFC) mediation of executive processes such as decision-making, 
long-term planning, impulse control and outcome prediction, along with its dense 
connectivity with the ventral tegmental area (VTA) and nucleus accumbens (NAc) 
(D'Esposito and Chen, 2006) raised interest as to whether chronic cocaine exposure 
induces alterations in this region. Indeed, studies subsequently found that neurochemical 
and electrophysiological modifications (Huang et al., 2007; Nasif et al., 2005; Steketee, 
2005) occur in the mPFC following sensitization. Of particular relevance to this study is 
the evidence suggesting mPFC pyramidal neurons are hyperexcitable in response to 
cocaine in sensitized animals (Nasif et al., 2005). Glutamatergic output from the mPFC to 
the VTA and NAc is necessary for the initiation and expression of sensitization (Li et al., 
1999) respectively, and so it is plausible that heightened excitatory input to such limbic 
structures represents a critical neuroadaptation that follows repeated cocaine exposure. 
Consequently, an understanding of the mechanisms that induce physiological changes in 
mPFC pyramidal cells could uncover avenues for the pharmacological prevention of 
relapse. 
 
In rodents, behavioral sensitization is observable as early as 1 day and at least as 
late as 1 year post repeated cocaine exposure however the processes that give rise to it are 
believed to change over time (Steketee, 2005). Cocaine-induced glutamate release in the 
mPFC, for example, is elevated in sensitized rats 1 and 7 days following repeated cocaine 
treatment, but returns to pre-drug exposure levels by 30 days post-exposure (Williams 
and Steketee, 2004). These early changes in neurotransmitter levels may be critical 
towards generating enduring alterations in mPFC responsivity. Indeed, mPFC Group II 
metabotropic glutamate receptor function is reduced during late sensitization, which 
should decrease inhibitory tone onto pyramidal neurons (Xie and Steketee, 2008). Thus, 
this suggests that, in the mPFC, changes in glutamate levels may mediate early 
sensitization, while glutamate receptor modifications may mediate late sensitization 
(Steketee, 2005).  
 
Group I metabotropic glutamate receptors (mGluRs) are primarily located 
postsynaptically in the mPFC and serve to increase the excitability of pyramidal 
projection neurons (Kew and Kemp, 2005). Group I mGluRs are Gq/G11-coupled and 
contain two subtypes: mGluR1 and mGluR5 (Kew and Kemp, 2005)). mGluR5 knock-
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out mice do not exhibit cocaine sensitization and allosteric modulators of this receptor 
have proven effective agents for preventing relapse to cocaine in animal studies (Kenny 
et al., 2003; Olive, 2009). Additionally, stimulation of Group I mGluRs has been shown 
to result in increased mPFC glutamate levels, which could, in turn, augment neuronal 
excitability (Bandrowski et al., 2003; Melendez and Kalivas, 2003). Collectively, this 
suggests that activation of mPFC Group I mGluRs may play a role in the behavioral 
sensitization to cocaine. Therefore, to better understand the contribution of mPFC Group 
I mGluRs to sensitization, experiments in this report tested whether repeated activation of 
Group I mGluRs in the mPFC could induce cross-sensitization to cocaine and whether 
this cross-sensitization was dependent on glutamatergic input from the mPFC to the 
VTA. Furthermore, selective mGluR1 and mGluR5 antagonists were co-administered 
with DHPG to determine which receptor was mediating cross-sensitization. Finally, the 
effects of mPFC Group I mGluR antagonism on the initiation and expression of cocaine 
sensitization were assessed. 
 
 
Materials and Methods 
 
 
Animals and Surgery 
 
Male Sprague Dawley rats (Harlan, Indianapolis, IN) weighing 250-300 grams at 
the time of surgery were housed under a 12-hour light/dark cycle and given free access to 
food and water. Animals were anesthetized with a ketamine (80 mg/kg) and xylazine (6.0 
mg/kg) cocktail (1.0 ml/kg) and placed in a stereotaxic apparatus (Kopf Instruments). An 
incision was made in the scalp and the skin was pulled back to expose the skull. The area 
was disinfected and burr holes were drilled into the skull. Three stainless steel screws that 
would later anchor the dental acrylic (Jet-Set, Lang Dental, Germany) skullcap were 
inserted into the burr holes. Guide cannulae were bilaterally implanted 1 mm above the 
mPFC (A/P +3.2 mm, M/L ±0.6 mm, D/V -3.5 mm) and/or VTA (A/P -4.8 mm, M/L 
±0.6 mm, D/V -7.4 mm) and dental acrylic was applied to secure them. Obturators (14 
mm, 32 gauge stainless steel) were inserted into the cannulae to prevent their blockade. 
Animals were housed individually following surgery and given one week to recover prior 
to the start of experiments. All procedures were carried out in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and 




Injections and Behavior 
 
Animals were placed in activity chambers (45 x 24 x 19 cm) for 60 min prior to 
injections to allow for proper adaptation. Drugs were administered into the mPFC and/or 
VTA using a Sage syringe pump that held two 1 µl syringes attached to stainless steel 
injectors (15 mm, 32 gauge) by PE 20 tubing and delivered drug at a rate of 0.5 µl/min 
and a volume of 0.5 µl/side. Injectors were left in place for 20 s following injections and 
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obturators were again inserted. In the experiments where a systemic injection followed a 
microinjection, cocaine (15 mg/kg) or saline (1.0 ml/kg) was injected intraperitoneally 5 
minutes after the microinjection. Animals were then placed back in the activity chambers 
and locomotor activity was monitored through a Digiscan system (Accuscan, Columbus, 
OH, USA) as previously described (Beyer and Steketee 2002). Data were collected for 
120 min post-injection and organized into 15 min bins.  
 
 
Histology and Statistics 
 
Following studies, animals were heavily anesthetized with sodium pentothal (333 
mg/kg) and perfused by intracardiac administration of phosphate-buffered saline (50 ml) 
and 10% formaldehyde (50 ml). Brains were sectioned, mounted onto gelatin-coated 
slides, stained with cresyl violet, and viewed through a light microscope to verify 
cannulae and injector placement as determined by a rat brain atlas (Paxinos and Watson 
1997). The time-course of the locomotor activity was analyzed using a two-way 
(treatment and time) repeated measure (time) ANOVA. Multiple comparisons were made 





Cocaine hydrochloride was purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). (s)-3, 5-DHPG (dihydroxyphenylglycine), MTEP hydrochloride (3((2-methyl-4-
thiazolyl)ethynyl)pyridine hydrochloride), CNQX (6-cyano-7-nitroquinoxaline-2,3-
dione), and YM 298198 hydrochloride (6-Amino-N-cyclohexyl-3-methylthiazolo[3,2-
a]benzimidazole-2-carboxamide hydrochloride) were all purchased from TOCRIS 
Bioscience (Ellisville, MO, USA). All drugs were diluted with isotonic saline (0.9 units 
sodium chloride). DHPG dosages were determined based on dose-response experiments 
conducted in our lab. Dosages of MTEP, YM298198, and CNQX were selected based on 







Daily DHPG/Cocaine Test. This set of experiments was designed to measure 
whether repeated intra-mPFC microinjections of the Group I mGluR agonist DHPG 
could induce cross-sensitization to systemic cocaine in naïve animals. DHPG (15 
nmol/side) or saline was microinjected into the mPFC once daily for 4 consecutive days. 
Seven days following the final injection, a challenge injection of cocaine was delivered 
(15 mg/kg, i.p.) and locomotor activity was monitored for 120 min.  
 
DHPG+MTEP and DHPG+YM298198. This set of experiments determined 
which of the two Group I mGluR subtypes (mGluR1 or mGluR5) was responsible for 
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DHPG-induced cross-sensitization to cocaine. In the experiments examining the role of 
mGluR5 in DHPG-induced cross-sensitization, DHPG (15 nmol/side) alone, 
DHPG+Group I mGluR antagonist MTEP (15 nmol/side), MTEP (15 nmol/side) alone, 
or saline was microinjected into the mPFC for 4 consecutive days and motor activity in 
response to a systemically administered challenge injection of cocaine was assessed 7 
days following the final microinjection.  
 
In the experiments examining the role of mGluR1 in DHPG-induced cross-
sensitization, DHPG (15 nmol/side), DHPG+Group I mGluR1 antagonist YM298198 (15 
nmol/side), YM298198 alone (15 nmol/side), or saline was microinjected into the mPFC 
for 4 consecutive days and motor activity in response to a systemically administered 
challenge injection of cocaine was assessed 7 days following the final microinjection. 
Separate groups of animals were used for the MTEP and YM298198 experiments. 
 
Daily Cocaine/DHPG Test. These experiments were designed to determine 
whether intra-mPFC DHPG produced a sensitized motor response in cocaine-sensitized 
rats relative to saline controls. Data from these experiments was also used to rule out the 
possibility that a single dose of DHPG induces heightened motor activity. In these 
experiments, rats were treated with systemic cocaine (15 mg/kg, i.p.) or saline for 4 
consecutive days. Following 7 or 21 days post-cocaine exposure, DHPG was infused into 




These experiments measured the effects of VTA AMPA receptor antagonism on 
intra-mPFC DHPG-induced cross-sensitization to cocaine. The AMPA receptor 
antagonist CNQX (1 nmol/side) or saline was microinjected into the VTA 5 min prior to 
microinjections of DHPG or saline into the mPFC for four consecutive days. A challenge 
injection of cocaine was administered 7 days following the final microinjection and 




Initiation. This set of experiments measured the effects of mGluR5 antagonism on 
the initiation of cocaine sensitization. On the first day of initiation experiments, animals 
were placed in the activity chambers for 60 min before either mGluR5 antagonist MTEP 
(15 nmol/side) or saline was microinjected into the mPFC five minutes prior to an i.p. 
injection of saline. Locomotor activity was then monitored for 120 min and these data 
were later analyzed for the purpose of determining any nonspecific effects of the 
antagonists. On the second day of initiation experiments, animals were placed in activity 
chambers for 60 min and then received an mPFC microinjection of either MTEP or saline 
that preceded by 5 min a systemic injection of saline or cocaine (15 mg/kg, i.p.). 
Locomotor activity was then recorded for 120 min. On the 3rd-5th days of these 
experiments, animals received the same treatment they received on the second day and 
were immediately placed back in their home cages following injections. Motor activity in 
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response to a challenge injection of saline or cocaine was measured six or seven days 
following the final microinjection, respectively.  
 
Expression. This set of experiments measured the effects of mGluR5 antagonism 
on the expression of cocaine sensitization at 7 and 21 of abstinence. Animals were given 
cocaine (15 mg/kg, i.p.) or saline injections for 4 consecutive days. Seven or 21 days 
following the last of the daily cocaine injections, mGluR5 antagonist MTEP (15 
nmol/side) or saline was microinjected into the mPFC five min prior to a challenge 
injection of cocaine (15 mg/kg, i.p.), and motor activity was monitored for 120 min. A 
day prior to the cocaine challenge, animals received an mPFC microinjection of either 
saline or MTEP (15 nmol/side) 5 min prior to a systemic injection of saline and 






Group I mGluR Stimulation in the mPFC Induces Cross-Sensitization to Cocaine 
 
Animals that had received once daily mPFC microinjections of the Group 1 
mGluR agonist DHPG over 4 consecutive days were significantly more active in 
response to cocaine 1 week later than were their saline counterparts (Treatment F 
(1,14)=6.425, p=0.0238; Time F(7, 98)=25.54, p<0.0001; Interaction F(7, 98)=3.213, 
p=0.0042), as evidenced through the monitoring of motor activity (photocell counts) in 
response to a challenge injection of cocaine (15 mg/kg, i.p.) over a 120 min period 
(Figure 1).The mean cocaine-induced activity level measured from DHPG-pretreated 
animals was comparable to that from cocaine-sensitized animals, suggesting that Group I 
mGluR stimulation in the mPFC results in cross-sensitization to cocaine. 
 
 
Cross-Sensitization Is Mediated by mGluR5  
 
In replication of the experiments above, repeated injections of DHPG into the 
mPFC induced cross-sensitization to cocaine (Figure 2). Co-administration of DHPG and 
the mGluR5 antagonist MTEP inhibited cross-sensitization (Treatment F(3,26)=3.518, 
p=0.0290; Time F(7,182)= 51.67, p<0.0001; Interaction F(21,182)=2.734, p=0.0002; 
Figure 2a). By contrast, co-administration of DHPG with mGluR1 antagonist 
YM298198 did not inhibit cross sensitization (Figure 2b). Taken together, these findings 
suggest the observed DHPG-induced cross-sensitization is mediated by mGluR5. Note: 
The average locomotor activity of the MTEP group was not significantly different from 
the DHPG group during the first time point due to the high activity level of one animal. 
The removal of this animal’s data from the analysis reveals significant difference 
between these two groups, however, the absence of infection or inaccurate injector 






Figure 1. Locomotor Response to a Challenge Injection of Cocaine. Locomotor 
response (photocell counts) to a challenge injection of cocaine (15 mg/kg, i.p.) is shown 
over a 120 min time period. Animals received mPFC microinjections of DHPG (15 
nmol/side) (n=8) or saline (n=8) for 4 consecutive days 7 days prior to the cocaine 


















































Figure 2. DHPG-Induced Cross-Sensitization Is Mediated by mGluR5. a) Locomotor 
response to a challenge injection of cocaine is shown over a 120 min time period. 
Animals received mPFC microinjections of DHPG+MTEP (15 nmol/side) (n=8), DHPG 
(15 nmol/side) (n=8), MTEP (15 nmol/side)(n=8), or saline (n=8) for 4 consecutive days 
one week prior to the cocaine challenge. *p< 0.05 compared to saline. +p< 0.05 compared 
to DHPG.b) Locomotor response to a challenge injection of cocaine is shown over a 120 
min time period. Animals received mPFC microinjections of DHPG+YM198298 (15 
nmol/side) (n=8), DHPG (15 nmol/side) (n=8), YM198298 (15 nmol/side) (n=8), or 
saline (n=8) for 4 consecutive days one week prior to the cocaine challenge. *p< 0.05 
compared to saline. 













































VTA AMPA Receptor Blockade Inhibits DHPG-Induced Cross-Sensitization 
 
Group I mGluR activation within the mPFC may be important for recruiting the 
VTA, which is critical for sensitization (Kalivas, 2001). Thus, the AMPA receptor 
antagonist CNQX or saline was microinjected into the VTA 5 min prior to intra-mPFC 
DHPG or saline to test whether DHPG-induced cross-sensitization relied on activation of 
the VTA (Figure 3). In agreement with this idea, intra-VTA CNQX blocked cross-
sensitization induced by intra-mPFC DHPG, AMPA receptor activation in the VTA is 
necessary for mPFC DHPG-mediated cross-sensitization (Treatment F(3, 21)=5.607, 
p=0.0005; Time F(7, 147)=73.85, p<0.0001; Interaction F(21, 147)=4.460, p<0.0001) 
(Figure 3).  
 
 
mPFC mGluR5 Blockade and Cocaine Sensitization 
 
Given that mPFC mGluR5 inhibition was sufficient to prevent the DHPG-induced 
cross-sensitization, it was important to test whether the initiation and/or expression of 
cocaine sensitization similarly relied on mGluR5 in the mPFC. mGluR5 inhibition via 
mPFC microinjections of MTEP was not sufficient to prevent the initiation of cocaine 
sensitization . Motor activity in response to a challenge injection of cocaine did not 
significantly differ between animals that had received saline or MTEP prior to their 
sensitizing cocaine injections; all animals that had received repeated cocaine exhibited a 
sensitized response to the cocaine challenge, indicating that mGluR5 blockade in the 
mPFC is not sufficient to prevent the establishment of cocaine sensitization (Figure 4). 
 
mGluR5 in the mPFC appears necessary for late, but not early, expression of 
sensitization. Animals received repeated i.p. injections of saline or cocaine (15 mg/kg)  7 
(Figure 5a) or 21 days (Figure 5b) prior to the cocaine challenge. Animals received an 
mPFC microinjection of either saline or mGluR5 antagonist MTEP 5 min prior to the 
cocaine challenge. Animals that had received repeated cocaine exhibited a sensitized 
response to the challenge regardless of whether they received an mPFC microinjection of 
saline or MTEP at 7 days (Treatment F(3, 23)=2.408, p=0.0931; Time F(7, 161)=107.5, 
p<0.0001; Interaction F(21, 161)=6.121, p<0.0001) (a), while only animals that received 
repeated cocaine and a saline microinjection before the cocaine challenge exhibited a 
sensitized response at 21 days (Treatment F(3, 25)=3.515, p=0.0297; Time F(7. 
175)=82.25, p<0.0001; Interaction F(21, 175)=6.195, p<0.0001) (b). Our results suggest 
mGluR5 antagonism in the mPFC is sufficient to prevent the expression of sensitization 
at 21, but not 7 days from the last cocaine injection, suggesting mGluR5 activity in the 






Figure 3. VTA AMPAR Blockade Prevents DHPG-Induced  Cross-Sensitization. 
Locomotor response to a challenge injection of cocaine in shown over a 120 min time 
period. Animals received four consecutive daily intra-VTA microinjections of saline or 
CNQX (1 nmol/side) followed by an intra-mPFC microinjection of saline or DHPG (15 
nmol/side) five minutes later. *p< 0.05 compared to saline. +p< 0.05 compared to DHPG. 














































Figure 4. Effect of mPFC mGluR5 Blockade on the Initiation of Sensitization. 
Locomotor response to a challenge injection of cocaine is shown over a 120 min time 
period. Animals received an mPFC microinjection of MTEP (15 nmol/side) or saline 5 
min prior to systemic cocaine or saline for 4 consecutive days one week prior to the 










































Figure 5. Effect of mPFC mGluR5 Blockade on the Expression of Sensitization. 
Locomotor response to a challenge injection of cocaine (15 mg/kg, i.p.) is shown over a 
120 min time period. Animals received systemic injections of cocaine (15 mg/kg, i.p.) or 
saline for four consecutive days 7 (a) or 21 (b) days prior to the cocaine challenge. On the 
day of the challenge, animals received an mPFC microinjection of MTEP (15 nmol/side) 
or saline five minutes prior to cocaine (15 mg/kg, i.p.). *p< 0.05 compared to 
saline/saline. +p<0.05 compared to cocaine/saline. Saline/saline: n=9; saline/cocaine: 
n=10; MTEP/saline: n=7; MTEP/cocaine: n=9. 
















































mGluR5 Activation Alone Does Not Produce a Sensitized Response in Sensitized 
Animals 
 
Given that intra-mPFC administration of DHPG induced cross-sensitization to 
cocaine, we tested whether DHPG could elicit a sensitized response in cocaine-sensitized 
rats. Locomotor activity in response to a challenge mPFC DHPG microinjection did not  
differ between saline- and cocaine-treated rats at 7 or 21 days following the last cocaine 
exposure (data not shown). Based on this data, it appears that mGluR5 activation in the 






Histological analysis was performed on the brains of all animals in the study, as 
described in the methods. Injector sites of animals included in the analysis were located 
in the prelimbic (Cg3 area) or infralimbic regions of the prefrontal cortex (Figure 6a, c). 
The majority of injector placements were +3.20 mm from Bregma. Injector locations for 
animals included in the VTA experiments were in the VTA, at -5.2 and -5.3 mm from 
Bregma (Figure 6b, d). Within each experimental group, several animals were 





The present studies demonstrate that repeated mGluR5 activation in the mPFC 
induces a cross-sensitization to cocaine that can be prevented through AMPA receptor 
blockade in the VTA, suggesting glutamatergic transmission from the mPFC to the VTA 
is necessary for this cross-sensitization to occur. Furthermore, mPFC mGluR5 blockade 
prevents the expression of late, but not early, cocaine sensitization, which may indicate 
that modifications in mPFC mGluR5 represent one lasting neuroadaptation that results 
from repeated cocaine exposure.  
 
We found that repeated local activation of group I mGluRs in the mPFC lead to 
cross-sensitization to cocaine in naïve rats. Further investigation showed that mGluR5, 
rather than mGluR1, was responsible for this effect and VTA AMPA receptor 
antagonism prevented it. Our results suggest glutamatergic input from mPFC pyramidal 
neurons to the VTA mediated the cross-sensitization we observed in response to repeated 
intra-mPFC DHPG. Glutamate in the VTA is known to be necessary for the initiation of 
sensitization (Kalivas and Alesdatter, 1993). In addition, sensitization is associated with 
enhanced glutamate release in the VTA and insertion of AMPA receptors lacking the 
GluR2 subunit (Fitzgerald et al., 1996; Kalivas and Duffy, 1998).  Furthermore, repeated 
AMPA injections into the VTA (Dunn et al., 2005) have been shown to induce cross-
sensitization to cocaine. Similarly, as was shown in the present report, repeated mPFC 
mGluR5 stimulation and subsequent glutamate release in the VTA may have activated 




Figure 6. Microinjection Placement in the mPFC and the VTA. Representative 
photomicrographs and stereotaxic atlas schematics of injection sites in the mPFC (a, c) 
and VTA (b, d). Top panels show injector placement in cresyl violet-stained coronal 
sections from representative brains. Bottom panels show illustrations of injector 
placement from all animals included in the analysis. Illustrations were derived from ‘The 
Rat Brain in Stereotaxic Coordinates’ (Paxinos and Watson, 1997). fmi=forceps minor of 
the corpus callosum; PBP=parabrachial pigmented nucleus; SNr=substantia nigra 













release in the nucleus accumbens (Giorgetti et al., 2001), a critical event common to 
virtually all drugs of abuse (Kuhar, 1991). Therefore, repeated mPFC DHPG 
administration may mimic some key processes that occur in response to repeated cocaine 
exposure and lead to sensitization, however, the mechanisms that fuel these processes 
may differ, as discussed below.  
 
One surprising aspect of our results is that while mGluR5 activation in the mPFC 
via DHPG is sufficient to induce sensitization, these receptors are not necessary for the 
initiation of sensitization to cocaine, as evidenced by the failure of the mGluR5 
antagonist MTEP to prevent initiation of cocaine-induced sensitization. One possible 
explanation for this is that while mGluR5 activation of pyramidal projection neurons to 
the VTA can induce sensitization, cocaine is capable of activating VTA dopaminergic 
cells independent of mPFC involvement. Indeed, intra-VTA cocaine administration has 
been shown to induce sensitization, as has the intra-VTA administration of the dopamine 
re-uptake inhibitor GBR 12909 (Cornish and Kalivas, 2001; Steketee, 1998). Through 
dopamine transporter blockade, cocaine increases dopamine levels in the VTA. This 
elevation in dopamine leads to glutamate release via activation of dopamine D1 receptors 
that consequently activates dopaminergic output neurons in the VTA (Cornish and 
Kalivas, 2001; Kalivas and Duffy, 1998). Furthermore, the systemic administration of 
cocaine may result in the activation of mPFC pyramidal neurons in ways that do not 
involve, or at least are not limited to, the stimulation of mGluR5. Thus, selective mGluR5 
blockade in the mPFC may not be sufficient to block initiation because dopaminergic 
projection neurons in the VTA are receiving glutamatergic input through means 
independent of mGluR5 activation in the mPFC.  
 
In contrast to the initiation experiments, our expression studies revealed that 
mGlur5 in the mPFC is necessary for the long-term expression of cocaine sensitization, 
but its stimulation alone is not sufficient to elicit a sensitized locomotor response in 
cocaine-sensitized animals.   
 
Our results show that mGluR5 blockade in the mPFC did not prevent the 
expression of sensitization at 7 days following repeated cocaine exposure, but did prevent 
it at 21 days. This may have occurred because cocaine-evoked mPFC glutamate levels are 
elevated during early sensitization (measured at 7-days after daily cocaine treatment) but 
return to baseline by late sensitization (30-days post cocaine exposure) (Williams and 
Steketee, 2004). mGluR5 blockade during early sensitization may not have been 
sufficient to decrease the excitability of mPFC pyramidal neurons because, in the 
presence of cocaine, there was enough glutamate available to stimulate AMPA receptors. 
However, when cocaine-induced glutamate levels normalize during late sensitization, 
mGluR5 may have a greater influence over neuronal excitability and its blockade at this 
point may reduce firing to a degree that prevents expression. A related possibility is that 
other cocaine-induced neurotransmitter and/or receptor changes that occur in the mPFC 
during late sensitization depend on mGluR5 function and mGluR5 antagonism at this 
stage could affect expression. This possibility is discussed in greater detail below. A third 
reason why mGluR5 blockade may have prevented late but not early expression is that 
the elevations in cocaine-induced glutamate levels during early sensitization may have 
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lead to increased activation of the peri-synaptically located mGluR5 and subsequent 
changes in receptor number, function, or downstream signaling that effectively altered 
mGluR5 regulation over neuronal firing in the mPFC. Such cellular modifications may 
not have been in place until late sensitization. 
 
While blockade of mGluR5 could prevent the expression of late sensitization, 
stimulation of these receptors with DHPG failed to produce a sensitized locomotor 
response in animals previously sensitized to cocaine. This result suggests that stimulation 
of mPFC mGluR5 is not sufficient to produce a locomotor response. While mGluR5 may 
result in activation of VTA neurons and dopamine release in the NAc, locomotor activity 
likely requires a greater level of dopamine that may only be achievable through the 
dopamine transporter blockade produced by cocaine.  
 
Some evidence indicates that mGluR5s, including those in the mPFC, may 
contribute to cocaine sensitization. Most importantly, mGluR5-null mice do not sensitize 
to or self-administer cocaine (Chiamulera et al., 2001). Additionally, mGluR5 stimulation 
results in an increase in mPFC neuronal excitability (Bandrowski et al., 2003; Marek and 
Zhang, 2008). The goal of the experiments delineated in this report was to uncover a 
possible role for mPFC mGluR5 in cocaine sensitization that could eventually shed more 
light on the mechanisms underlying the increased excitability of mPFC pyramidal 
neurons following repeated cocaine exposure. Support for an increase in intrinsic mPFC 
neuronal excitability comes from evidence demonstrating an increase in L-type calcium 
channel current (Nasif et al., 2005) and number (Ford et al., 2009) following repeated 
cocaine administration. 
 
A decrease in inhibitory tone is suggested by studies showing a reduction in 
mPFC Group II mGluR (Xie and Steketee, 2008), D2 (Beyer and Steketee, 2002; Liu and 
Steketee, 2011) and GABAB (Steketee and Beyer, 2005) receptor function following 
repeated cocaine exposure (Bowers et al., 2004). An increase in excitatory drive may 
result from the elevation in mPFC dopamine levels that occurs during late sensitization 
(Williams and Steketee, 2005). Evidence suggests mPFC pyramidal neurons fluctuate 
between states of high and low excitability and dopamine D1 and D2 receptors play 
opposing roles in the regulation of these states. D1 receptor activation is believed to 
increase and then maintain the high excitability state while D2 receptor stimulation is 
thought to convert pyramidal cells from the high to the low excitability state (Seamans 
and Yang, 2004; Steketee, 2005). The combination of the reduction in dopamine D2 
receptor function and increase in intrinsic neuronal excitability may pave the way for 
increased dopamine D1 tone and the consequent perpetuation of a high-excitability state 
in mPFC pyramidal projection neurons. It has been suggested that mGluR5 is essential 
for maintaining neuronal firing in the mPFC (Homayoun and Moghaddam, 2010). The 
prevention of late-stage expression shown in the present study raises the question of 
whether the regulatory role of mPFC mGluR5 serves to perpetuate the high-activity state 
that could result from loss of D2 receptor function following repeated cocaine exposure 
(Beyer and Steketee, 2002; Bowers et al., 2004). In this scenario, no drug-induced 
alterations would necessarily have to take place in mGluR5, however, its activation 
would nevertheless be critical for late expression. Acute mPFC mGluR5 blockade 
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immediately prior to cocaine exposure during late sensitization would prevent or 
attenuate the glutamatergic transmission to the NAc required for expression. Further 
studies should address whether repeated cocaine leads to changes in mPFC mGluR5 
function or coupling, or if mGluR5 simply holds greater influence over pyramidal cell 
firing due to changes in other receptors or neurotransmitters following sensitization.  
 
A caveat of the present study is the possibility that intra-mPFC-administered 
drugs activated off-target receptors and the consequent stimulation of these receptors was 
partially responsible for the effects we observed. While DHPG has proved to be highly 
selective for Group I mGluRs, it has been shown that it can interact with NMDA 
receptors under certain conditions (Wisniewski and Car, 2002)). mGluR5 antagonist 
MTEP is preceded by 2-methyl-6-(phenylethynyl) pyridine hydrochloride (MPEP). In 
addition to being a selective, noncompetitive mGluR5 antagonist, evidence suggests 
MPEP acts on mGluR1d and NMDA receptors (Lea and Faden, 2006). By contrast, 
MTEP has far less potential for off-target effects and is considered the most selective and 
least problematic of all mGluR5 antagonists (Lea and Faden, 2006)). YM298198 is a 
potent mGluR1 antagonist with very few off-target effects (Fukunaga et al., 2007). While 
we recognize the possibility of an unintended site playing a role in our results, our failure 
to observe DHPG-induced cross-sensitization in animals that additionally received 
mGluR5 antagonist MTEP suggests mGluR5 in the mPFC was primarily responsible for 
our findings. AMPA receptor antagonist CNQX also acts as a weak antagonist at the 
glycine site of NMDA receptors, however, since our goal was to suppress mPFC-
mediated glutamatergic input to VTA dopaminergic projection neurons, this action would 
not compromise the integrity of our findings.  Finally, the lack of significant difference in 
cocaine-induced locomotion between animals that received saline and those that received 
the drug alone (e.g. mPFC saline vs. mPFC YM298198) suggests the drugs we employed 
did not induce any measurable changes in behavior. 
  
In conclusion, the experiments delineated in this paper show that mGluR5 
activation in the mPFC can induce a cross-sensitization to cocaine that can be prevented 
through the blockade of AMPA receptors in the VTA. Furthermore, our studies show that 
mGluR5 inhibition in the mPFC prevents the expression of late, but not early, behavioral 
sensitization to cocaine. The suggested involvement of mGluR5 in late-stage sensitization 
is particularly important because the cocaine-induced changes that may be occurring in 
this receptor could potentially contribute to the persistence of drug-seeking behavior and 
propensity for relapse, especially since these alterations are taking place in the PFC. 
Taken together, the data demonstrate that mPFC mGluR5s are sufficient, but not 
necessary for the initiation of cocaine sensitization and necessary, but not sufficient for 
the expression of cocaine sensitization.  These results suggest a possible role for mPFC 





Chapter 3. Metabotropic Glutamate Receptor 5 in the Medial Prefrontal Cortex: 





Glutamatergic input from the medial prefrontal cortex (mPFC) to the ventral 
tegmental area (VTA) and the nucleus accumbens (NAc) is necessary for the initiation 
and expression, respectively, of the behavioral sensitization to cocaine (Pierce et al., 
1998; Steketee, 2003)). It has been demonstrated that mPFC pyramidal projection 
neurons become hyperexcitable following repeated cocaine exposure (Nasif et al., 2005) 
(Ford et al., 2009) (Hu, 2007), an event that would ultimately result in increased 
glutamatergic input to the VTA and the NAc. Imaging studies in human addicts have 
shown a similar increase in mPFC activity in response to cocaine and related cues as well 
as a decrease in responsivity to non-drug stimuli (Goldstein and Volkow, 2011). This 
heightened neuronal attentiveness to cocaine and its cues at the expense of non-drug 
stimuli may play a significant role in the exceedingly high relapse rate of cocaine addicts. 
Thus, a comprehensive understanding of the regulation of mPFC cell excitability in the 
addicted brain could potentially lead to effective pharmacotherapies to reduce the risk of 
relapse. 
  
Metabotropic glutamate receptor 5 (mGluR5), a Gq/G11-coupled Group I 
receptor abundant in corticolimbic regions, has been shown to influence neuronal 
excitability (Homayoun and Moghaddam, 2010; Kew and Kemp, 2005). mGluR5 
stimulation in mPFC, hippocampal, and nigral slices results in excitatory postsynaptic 
potentials (EPSPs), depolarization, and increased firing frequency (Marek and Zhang, 
2008) (Fitzjohn et al., 1999; Homayoun and Moghaddam, 2010; Marino et al., 2001). By 
contrast, mGluR5 blockade in the mPFC reduced firing frequency by about fifty percent 
(Homayoun and Moghaddam, 2006). Moreover, the firing rate of neurons with the 
highest baseline firing rate was reduced following antagonist administration to a greater 
extent than that of neurons with a lower pre-antagonist firing rate (Homayoun and 
Moghaddam, 2006; Homayoun and Moghaddam, 2010) possibly suggesting mGluR5 
activity can substantially influence the total output of the mPFC. In recent years, studies 
have implicated mGluR5 in cocaine addiction. mGluR5-null mice do not sensitize to 
cocaine (Chiamulera et al., 2001) and systemic administration of mGluR5 antagonists 
prevents sensitization and reinstatement (Martin-Fardon and Weiss, 2012; Platt et al., 
2008). Selective manipulation of mGluR5 in reward-processing brain regions has also 
affected addiction-related behaviors. mGluR5 blockade in the NAc prevented drug-
seeking behavior, while mGluR5 stimulation enhanced it (Wang et al., 2012). In the 
mPFC, repeated mGluR5 activation induced cross-sensitization to cocaine, while 
mGluR5 antagonism attenuated cocaine-induced locomotor activity in sensitized rats 
during late expression (Timmer and Steketee, 2012). Impaired cue-induced reinstatement 
was demonstrated following the selective knock-down of mGluR5 in dopamine D1 
receptor-expressing neurons, suggesting mGluR5 is important in the formulation of 
associations between cocaine and previously unrelated stimuli (Novak et al., 2010).  
 31
Taken together, the abovementioned evidence suggests mGluR5 activation in the 
mPFC may influence pyramidal cell output and consequently alter glutamatergic input to 
the VTA and NAc. The present study examined the effects of mPFC mGluR5 activation 
on glutamate levels in the mPFC, VTA, and NAc during early and late sensitization.  
 
 
Materials and Methods 
 
 
Animals and Surgery 
 
All animal procedures were carried out in accordance with the National Institutes 
for Health Guide for the Care and Use of Laboratory Animals and all experiments were 
approved by the University of Tennessee Health Science Center Animal Resources 
Advisory Committee. Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 
275-300 g at the time of surgery were housed under a 12-hour light/dark cycle and 
provided ad libitum access to food and water. Animals were anesthetized with a ketamine 
hydrochloride (80 mg/kg, i.p.) and xylazine (6 mg/kg, i.p.) cocktail and placed in a 
stereotaxic instrument (Kopf Instruments). Microdialysis cannulae (20 gauge, 14 mm, 
stainless steel) were unilaterally placed 3 mm above the mPFC (A/P +3.2, and M/L +.6 
mm from bregma; -1.5 mm from dura) and either the VTA (A/P -4.8 mm and M/L +.6 
mm from bregma; -5.4 mm from dura) or NAc (A/P -1.4 mm and M/L +1.4 mm from 
bregma; -5.0 mm from dura). Obturators (14 mm, 25 gauge, stainless steel) were inserted 
in the cannulae to prevent occlusion. Animals were given at least seven days for recovery 
prior to the commencement of experiments.  
 
 
Cocaine Pretreatment  
 
Intraperitoneal injections of either cocaine (15 mg/kg) or saline (1 mL/kg) were 
administered in the animals’ home cages for four consecutive days, with the fourth 
injection day preceding the microdialysis experiment by one, seven, or twenty-one days. 
Distinct groups of animals were used for each condition. 
 
 
In Vivo Microdialysis 
 
Microdialysis probes (2 mm active membrane) were inserted into the cannulae 
and dialysis buffer (2.7 mM KCl, 140 mM NaCl , 1.2 mM CaCl, 1.2 mM MgCl; pH: 7.4 
with phosphate-buffered saline) began infusing three hours prior to the start of sample 
collection. Samples were collected every 20 minutes in microcentrifuge tubes containing 
10 uL of 0.05 mM HCL. Four initial baseline samples were collected prior to Group I 
mGluR agonist DHPG (dihydroxyphenylglycine; TOCRIS) infusion through the dialysis 
probe. Three concentration (0.5 mM, 5 mM, 50 mM) of DHPG were infused in an 
increasing manner and four samples were collected during each concentration. Following 
collection, samples were stored at -80°C prior to analysis. 
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High Performance Liquid Chromatography 
 
Sample glutamate levels were analyzed using a fluorescence spectrophotometer 
system as previously described (Xie and Steketee 2008). Samples were derivatized (20 
uL sample+20 uL fluoraldehyde) and 25 uL of the mixture was injected onto a reversed-
phase column. The mobile phase (62 mM NaH2PO4, 0.5% v/v tetrahydrofuran, 40% v/v 
methanol; pH=6.3 with 6 N NaOH) flowed at a rate of 1 mL/min. Glutamate was 
detected at an excitation wavelength of 260 nm and an emission wavelength of 455 nm. 




Locomotor Activity Analysis 
 
Cocaine-induced locomotor activity was measured in all animals between 1 and 3 
days following experiments to ensure pretreatment effectiveness. Animals were placed in 
activity chambers (45 x 24 x 19 cm) for 60 min prior to cocaine administration (15 
mg/kg, i.p.) to allow for adaptation, and then locomotor activity was monitored for 120 





Subsequent to experiment completion, animals were deeply anesthetized with 
sodium pentothal (333 mg/kg) and intracardially perfused with phosphate-buffered saline 
(50 mL) followed by 4% formaldehyde. Brains were removed from the skull cavity and 
allowed to sit in a formaldehyde-filled vial for at least a week prior to sectioning. Coronal 
slices (100 um) were cut using a vibratome, mounted on gelatin-coated slides, and stained 
with cresyl violet. Probe placement was verified using light microscopy and a rat brain 
atlas (Paxinos and Watson 1997) and data from animals with incorrect probe placements 





Microdialysis data were converted to percentage-of-baseline values prior to 
analysis. The baseline for each data set was acquired by averaging the 3 most consistent 
values of the 4 initial baseline samples. Microdialysis data were analyzed using a two-
way repeated measures analysis of variance (ANOVA) followed by a modified least 
significances (LSD) test (Milliken and Johnson 1984), if necessary. Behavioral data were 









DHPG was purchased from Tocris Bioscience (Ellisville, MO, USA) and cocaine 
hydrochloride was purchased from Sigma Chemical Company (St. Louis, MO, USA). All 








Figure 7 shows motor activity recorded in response to a challenge injection of 
cocaine administered within 72 hours following microdialysis experiments for saline- and 
cocaine-pretreated rats. Data from all three time points were pooled and analyzed using 
an unpaired t-test. Cocaine-pretreated rats were significantly more active in response to 
the cocaine challenge than saline-pretreated controls (t=7.755, p<0.0001), suggesting that 
repeated cocaine induced sensitization. 
 
 
In vivo microdialysis 
 
Figure 8 illustrates the effects of intra-mPFC DHPG infusion (0.5, 5 and 50 uM) 
on mPFC glutamate levels in sensitized and non-sensitized rats at 1, 7, and 21 days 
following the last injection of cocaine or saline. The data were initially analyzed using a 
two-way repeated measures ANOVA. When an interaction effect was observed, further 
analysis using a modified least significant differences (LSD) test (Milliken and Johnson 
1984) was carried out to determine the time point(s) at which the difference occurred.  
  
Intra-mPFC DHPG administration increased mPFC glutamate levels at 7 days 
post-injection in rats that had previously received repeated cocaine but not saline (Figure 
8a) (Interaction:F(14, 364)=2.64, p=0.0010; Treatment: F(1, 364)=8.440, p=0.0074; 
Time: F (14, 364)=1.977, p=0.0186). No significant differences in extracellular mPFC 
glutamate levels were observed between two groups at 1 (Figure 8b) or 21 (Figure 8c) 
days post-injection, however, an interaction effect approached significance at 1 day 
withdrawal (1 Day: Interaction: F(14, 336)=1.703, p=0.0534; Treatment: F(1, 
336)=4.948, p=0.0358; Time: F(14, 336)=2.161, p=0.009) (21-Days: Interaction: F(14, 
322)=1.424, p=0.1399; Treatment: F(1,322)=0.02453, p=0.8769; Time: F(14, 
322)=1.978, p=0.0189)Baseline glutamate levels between cocaine- and saline-pretreated 
rats did not differ significantly at any of the three time points.  
 
Figure 9 shows the effects of intra-mPFC DHPG administration (0.5, 5 and 50 
uM) on glutamate levels in the NAC in cocaine- and saline-pretreated rats at 1, 7 and 21 
days post-injection. Data were analyzed using a two-way repeated measures ANOVA 




Figure 7. Effect of Repeated Cocaine Exposure on Cocaine-Induced Locomotion. 
Locomotor behavior (photocell counts) in response to a challenge injection of cocaine is 























Figure 8. Effect of Intra-mPFC mGluR5 Activation on mPFC Glutamate Levels. 
mPFC glutamate levels (shown as % of baseline) are displayed over 240 min for cocaine-
sensitized and control animals in response to 3 concentrations of DHPG (0.5, 5, 50 uM) 
at 1(a), 7(b), and 21(c) days withdrawal. *=p<0.05 between saline and cocaine animals.  
  
























































































Figure 9. Effect of Intra-mPFC mGluR5 Activation on NAc Glutamate Levels. NAc 
glutamate levels (shown as % of baseline) are displayed over 240 min for cocaine-
sensitized and control animals in response to 3 concentrations of DHPG (0.5, 5, 50 uM) 
at 1(a), 7(b), and 21(c) days withdrawal. *=p<0.05 between saline and cocaine animals.  
















































































When infused into the mPFC, DHPG significantly increased NAC glutamate 
levels in cocaine-pretreated rats at 21 days post-injection (Figure 9c) (Interaction: F(14, 
140)=1.963, p=0.0249; Treatment: F(1, 140)=7.373, p=0.0217; Time: F(14, 140)=1.431, 
p=0.1461). NAC glutamate levels did not differ between cocaine- and saline-pretreated 
rats at 1 (Figure 9a) or 7 (Figure 9b) days post-injection (1 Day: Interaction: F(14, 
168)=0.4758, p=0.9435; Treatment: F(1, 168)=0.04225, p=0.8406; Time: F(14, 
168)=0.9407, p=0.5167) (7 Days: Interaction: F(14, 154)=1.233, p=0.2566; Treatment: 
F(1, 154)=2.150, p=0.1706; Time: F(14, 154)=1.018, p=0.4386). There were no 
significant differences in baseline glutamate levels between the two groups at any of the 
three time points. 
 
Figure 10 depicts VTA glutamate levels following intra-mPFC DHPG infusion 
(0.5, 5 and 50 uM) in cocaine- and saline-pretreated rats at 1 (Figure 10a), 7 (Figure 
10b) and 21 (Figure 10c) days post-injection. The data was analyzed using a two-way 
repeated measures ANOVA.  
 
Intra-mPFC DHPG administration did not differentially affect VTA glutamate 
levels in saline- and cocaine-pretreated rats at 1, 7 or 21 days post-injection, however, a 
trend towards increased glutamate levels in cocaine-pretreated rats was observed at 7 
days post-injection (Figure 10b) (1 Day: Interaction: F(14, 140)=0.8216, p=0.6447; 
Treatment: F(1, 140)=0.0042, p=0.9491; Time: F(14, 140)=1.071, p=0.3888) (7 Days: 
Interaction: F(14, 168)=1.084, p=0.3755; Treatment: F(1, 168)=5.729, p=0.0339; Time: 
F(14, 168)=0.7618, p=0.07090) (21 Days: Interaction: F(14, 154)=0.8385, p=0.6266; 
Treatment: F(1, 154)=0.7894, p=0.3933; Time: F(14, 154)=1.032, p=0.4245). Baseline 
glutamate levels did not differ significantly between the two groups at any of the three 





Photomicrographs of typical microdialysis probe tracks in the mPFC, NAc and 
VTA are shown in Figure 11. In the mPFC, dialysis probes were located in the Cg3 or 
infralimbic regions (Figure 11a). Dialysis probes in the NAc were medial to the anterior 
commissure (ac) and within the core or shell of the NAc (Figure 11b). In the VTA, 
microdialysis probes were medial to the substantia nigra (SnC, SnR) and adjacent to the 





The effects of mPFC mGluR5 activation on mPFC, VTA and NAc glutamate 
levels in sensitized and non-sensitized animals were explored in the present study. We 
did not observe an effect of intra-mPFC mGluR5 activation on glutamate levels in any 
brain region at any time point in control animals. However, our data show that mPFC 





Figure 10. Effect of Intra-mPFC mGluR5 Activation on VTA Glutamate Levels. 
VTA glutamate levels (shown as % of baseline) are displayed over 240 min for cocaine- 
sensitized and control animals in response to 3 concentrations of DHPG (0.5, 5, 50 uM) 


















































































Figure 11. Microdialysis Probe Placement in the mPFC, NAc, and VTA. 
Representative photomicrographs of microdialysis probe sites in the mPFC (a), Nac (b), 
and VTA (c). fmi=forcepts minor corpus callosum, ac=anterior commissure, 
PBP=parabrachial pigmented nuclei, PN=paranigral nuclei, SnC=substantia nigra 






21 days, withdrawal in sensitized rats. In the NAc, intra-mPFC mGluR5 activation leads 
to elevated glutamate levels at 21, but not 7 or 1, days post-injection in sensitized 
animals. mPFC mGluR5 stimulation did not significantly alter glutamate levels in the 
VTA at any time point, however, a subset of animals exhibited an increase in glutamate 
levels at 7 days withdrawal. These results imply repeated cocaine exposure leads to a 
transient mPFC mGluR5-mediated glutamate increase in the mPFC and a delayed, but 
possibly lasting, mPFC mGluR5-induced increase in NAc glutamate levels.  
 
mPFC mGluR5 and mPFC Glutamate 
 
The present data show that intra-mPFC mGluR5 activation increases mPFC 
glutamate levels at 7, but not 1 or 21, days following the last sensitizing cocaine 
injection. This suggests repeated cocaine exposure may transiently alter mGluR5 activity 
in a manner that yields mPFC-specific glutamate increases, or induce temporary 
mGluR5-independent neuronal changes that result in heightened glutamate release 
following mGluR5 stimulation. mGluR5 is generally located postsynaptically and serves 
to increase the excitability of mPFC pyramidal neurons (Homayoun and Moghaddam, 
2010; Kew and Kemp, 2005).  
 
Given that the mPFC contains projections that terminate in various brain regions 
(Hoover and Vertes, 2007; Sesack et al., 1989), including the mPFC, one possibility is 
that sensitization-induced changes occur earlier in mGluR5-bearing mPFC-projecting 
neurons than in mGluR5-containing neurons that project to other brain areas, such as the 
NAc. As discussed in the following section, we observed elevated NAc glutamate levels 
at 21 days withdrawal in sensitized rats in response to mPFC mGluR5 stimulation, 
suggesting mPFC mGluR5 increases neuronal firing during late sensitization. It is 
conceivable that early glutamate release via local mPFC neurons play a role in facilitating 
later adaptations in NAc projections. A previous study demonstrated increased cocaine-
induced mPFC glutamate in sensitized animals at 7, but not 30, days withdrawal 
(Williams and Steketee, 2004), suggesting transient mPFC glutamate alterations occur 
during early sensitization. mGluR5 activation in a select group of local mPFC projection 
neurons may contribute to early mPFC glutamate elevations. Selective mediation of 
sensitization by a subset of neurons was recently demonstrated in the NAc. Sensitization-
induced increases in AMPA and NMDA receptors were shown in the neurons associated 
with sensitization, but not the ones that were unassociated (Koya et al. 2012).  Future 
studies examining potential differences in mGluR5 distribution and function on distinct 
projection neurons within the mPFC could be useful.  
 
 
mPFC mGluR5 and NAc Glutamate 
 
Intra-mPFC activation of mGluR5 increased NAc glutamate levels at 21, but not 1 
or 7, days withdrawal in sensitized animals. This escalation likely results from two 
factors. The first is the reduction in cysteine-glutamate antiporter function that decreases 
intra-NAc baseline glutamate levels and is known to occur during late sensitization 
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(Baker et al., 2003) and the second is the increased firing of NAc-terminating projections 
within the mPFC following mPFC mGluR5 activation. 
 
Evidence suggests alterations in the NAc play a significant role in the loss-of-
control over drug-seeking behavior that ultimately leads to relapse. In agreement with 
this, a number of studies have uncovered lasting, NAc-specific changes observable 
during late, but not early, withdrawal, and many of these adaptations involve glutamate 
transmission and plasticity (Churchill et al., 1999; Kourrich et al., 2007; Schumann and 
Yaka, 2009). As previously mentioned, sensitization is associated with cocaine-induced 
hyperexcitability of mPFC projection neurons in rodents (Ford et al., 2009; Nasif et al., 
2005) (Hu, 2007), and imaging studies in addicts show heightened mPFC activity in 
response to cocaine and cocaine-related cues (Goldstein and Volkow, 2011). Taken 
together, one might suppose that the combination of low baseline glutamate levels within 
the NAc and heightened cocaine-induced mPFC glutamatergic transmission to the NAc 
sets the stage for cocaine and cocaine-associated cues to stimulate NAc output, thus 
facilitating addictive behavior. Our finding that intra-mPFC mGluR5 activation increases 
NAc glutamate levels during late sensitization may suggest mGluR5 contributes to the 
hyperexcitability of mPFC pyramidal neurons following repeated cocaine exposure. Our 
present data also corroborates our previous finding that mPFC mGluR5 blockade 
prevents late, but not early sensitization (Timmer and Steketee, 2012).  
 
 
mPFC mGluR5 and VTA Glutamate 
 
mPFC mGluR5 activation did not significantly increase glutamate levels in the 
VTA in sensitized or control animals. However, we observed that a subset of sensitized 
animals showed substantially higher glutamate levels at 7 days withdrawal following 
intra-mPFC mGluR5 stimulation, but the extent of variability between the animals that 
displayed an increase and those that did not prevented a significant interaction effect. 
  
One interesting aspect of our findings is the lack of a glutamate increase in the 
VTA at 21 days abstinence in sensitized rats following intra-mPFC mGluR5 activation. 
In the previous two paragraphs, we propose that cocaine-induced alterations in mPFC 
mGluR5 may occur earlier in local mPFC projection neurons, and later in projections to 
other brain areas. Our data showing that intra-mPFC mGluR5 activation increases NAc 
glutamate at 21 days withdrawal in sensitized animals supports this explanation, however 
if mGluR5 stimulation induces greater excitation of extra-mPFC mGluR5-bearing 
projection neurons during late sensitization, one might expect a concomitant increase in 
VTA glutamate levels. One possible reason why we did not observe a glutamate increase 
in the VTA is because mPFC projections to this region did not become more excitable 
following mGluR5 stimulation, or glutamate increases in the VTA were too small to 
measure. However, as previously mentioned, we did observe increased VTA glutamate 
following intra-mPFC mGluR5 activation in roughly half of sensitized animals at 7 days 
withdrawal, suggesting alterations in mPFC mGluR5 may have occurred on mPFC-VTA 
projections during early sensitization. We may not have observed this in all of our 
animals due to differences in microdialysis probe placement within the mPFC or VTA, or 
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the degree of sensitization within the animals, which is known to vary (Hooks et al., 
1991). In support of this, the VTA is thought to be involved with the initiation phase of 
sensitization and cocaine-induced alterations demonstrated to occur in this region tend to 
be transient (Pierce and Kalivas, 1997; Zhang et al., 1997).  
  
In a previous study, we demonstrated that repeated intra-mPFC mGluR5 
stimulation induced a cross-sensitization to cocaine that could be prevented via AMPA 
receptor blockade within the VTA prior to mPFC mGluR5 activation. This finding led us 
to hypothesize that repeated mPFC mGluR5 stimulation increases VTA glutamatergic 
transmission, thus facilitating dopaminergic input from the VTA to the NAc and inducing 
sensitization. Based on these results, glutamate increases in the VTA following mPFC 
mGluR5 activation might be expected in saline control animals. One potential reason 
why we did not observe an increase is that while mPFC mGluR5 activation induces 
glutamate release in the VTA sufficient to activate dopaminergic projection neurons, the 
glutamate fluctuations are too slight to measure via microdialysis. A second possibility is 
that intra-mPFC mGluR5 activation increases VTA glutamate to a greater extent with 
each successive application of the agonist. Perhaps we would have observed an increase 
in VTA glutamate levels following intra-mPFC mGluR5 activation if we measured the 





Data from the present study show mPFC mGluR5 activation increases mPFC 
glutamate levels during early, and NAc glutamate levels during late, sensitization. 
Excitatory input from the mPFC to the NAc is necessary for the expression of 
sensitization (Pierce et al., 1998) (Steketee, 2003) and mPFC projection neurons are 
hyperexcitable in response to cocaine following sensitization (Nasif et al., 2005) (Ford et 
al., 2009; Hu, 2007)). mGluR5 is a modulatory receptor that has been shown to increase 
firing frequency in mPFC pyramidal neurons (Fitzjohn et al., 1999; Marek and Zhang, 
2008; Marino et al., 2001) (Homayoun and Moghaddam, 2010). Our results indicate 
mGluR5 within the mPFC increases firing of mPFC-Nac projections during late 
sensitization, pointing to a role for mGluR5 in sensitization-affiliated neuronal 
hyperexcitability in the mPFC. Our data showing an mGluR5-mediated mPFC glutamate 
increase at 7 days withdrawal may suggest early changes in the excitability of local 
mPFC projections that are transient, but influential in shaping later alterations in NAc 
projection neurons.  
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Chapter 4. Role of Metabotropic Glutamate Receptor 5 in the Medial Prefrontal 





Cocaine addiction carries a notoriously high risk of relapse, even following years 
of abstinence. Consequently, the discovery of ways to prevent relapse is the predominant 
goal of addiction research. There is increasing evidence that mGluR5 modulation may 
attenuate the risk of relapse. Systemic administration of an mGluR5 antagonist dose-
dependently decreased cue- and cocaine-induced reinstatement (Backstrom and Hyytia, 
2006; Kumaresan et al., 2009) and it has been suggested the effect of mGluR5 
antagonism on cocaine self-administration results from an mGluR5-mediated decrease in 
the rewarding properties of cocaine (Kenny et al., 2005; Platt et al., 2008). A primary 
way in which mGluR5 antagonism could attenuate the rewarding effects of cocaine is by 
reducing transmission through the mesocorticolimbic circuit. Within the mPFC, mGluR5 
is primarily located postsynaptically on pyramidal projection neurons that terminate in 
reward-associated regions such as the VTA and NAc, and the activation of mPFC 
mGluR5 has been shown to increase neuronal excitability (Homayoun and Moghaddam, 
2010; Kew and Kemp, 2005). Evidence suggests cocaine sensitization leads to increased 
cocaine-induced excitability of mPFC pyramidal neurons (Nasif et al., 2005), a 
consequence of which might be increased glutamatergic input to the VTA and NAc. One 
might expect that if mPFC mGluR5 activation increased neuronal activity in sensitized 
animals, intra-mPFC mGluR5 blockade would prevent and intra-mPFC mGluR5 
stimulation would facilitate behavioral and neurochemical indicators of addiction. In 
support of this, we previously demonstrated that intra-mPFC mGluR5 blockade 
prevented late expression (Timmer and Steketee, 2012) and intra-mPFC mGluR5 
activation increased glutamate levels in the NAc at 21-days withdrawal in sensitized 
animals (Chapter 3). We consequently became interested in the relationship between 
mPFC mGluR5 and drug-seeking, a behavior that can be initiated by cocaine or 
associated cues and that, most importantly, precedes relapse  
 
Both contingent and noncontingent models of addiction have yielded a great deal 
of information over the past few decades, however, there has been some debate over the 
validity of noncontingent methods. Conversely, while it is not without its flaws (Epstein 
et al., 2006), the self-administration model possesses more “real-world” attributes of 
addiction because the animal is choosing to take the drug rather than receiving it from the 
experimenter. However, self-administration experiments can be more time-consuming 
and cumbersome than noncontingent studies of sensitization. Therefore, an ideal strategy 
would be to employ noncontingent methods as a first-pass screening for prospective 
influential factors in addiction and, if a relationship is found, contingent experiments may 
follow. Thus, an ancillary inquiry within this study is whether our previous results 
obtained with a noncontingent method are consistent with our current findings. 
 
Therefore, in the present study, we investigated in a self-administration paradigm 
the effect of mPFC mGluR5 blockade on cue- and drug-induced drug seeking behavior 
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following extended cocaine withdrawal. Our results indicate a nonsignificant trend 
towards an attenuation of cue-induced, but not drug-induced, drug-seeking following 






Animals and Surgery 
 
Male Sprague-Dawley (Harlan, Indianapolis, IN) rats weighing 275-300 g at the 
time of surgery were housed under a reverse 12 h light/dark cycle and had ad libitum 
access to food and water. Animals were anesthetized with a ketamine (80 
mg/kg)/xylazine (6.0 mg/kg) cocktail (1.0 ml/kg, i.p.). Jugular catheters were composed 
of an injection pedestal (Plastics One) bent to 90 degrees and attached to silastic tubing. 
The pedestal was affixed to hernia meshing via dental acrylic (Jet-Set, Lang Dental, 
Germany). The back-mounted catheters were threaded into the jugular vein and lowered 
to a point just above the heart. Following insertion, heparinized saline was injected 
through the pedestal to confirm clarity and animals were given Rimadyl (1ml/kg, i.p.). 
Immediately following catheterization surgery, animals heads were placed in a 
stereotaxic frame (Kopf Instruments) and bilateral cannulae (25 gauge, 14 mm, stainless 
steel) were inserted 1 mm above the mPFC (A/P+3.3 mm; M/L+.6 mm; D/V -3.5 mm). 
Obturators (32 gauge, 14 mm, stainless steel) were implanted in the cannulae to prevent 
occlusion. Animals were given at least one week of recovery time prior to the 
commencement of experiments. Procedures were carried out in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals and all experiments were approved by 




Cocaine Self-Administration Training 
 
Rats were trained to self-administer cocaine via lever-press in an operant box 
(Med Associates) containing 2 levers (active and inactive) and 2 cue lights. Animals were 
first trained under a FR1 schedule that increased to FR2 once criterion (9 correct 
responses) was met. Once FR2 criterion (18 correct responses) was met, the schedule 
increased to FR5 and continued as such for the remainder of the training phase. 0.05 mL 
of cocaine (0.25 mg) was delivered over the course of 1 second in response to the correct 
number of lever presses on the active lever in the presence of the cue light. The training 
session ended after 3 hr or 9, 18 or 29 infusions for the FR1, FR2 and FR5 schedules, 
respectively. Animals were trained every day for ten days and considered to have learned 
the task if 29 infusions were obtained for at least the final 3 days of training. Animals that 
did not meet this criteria were excluded from the study. After the final training day, 






Intra-mPFC microinjections were made using stainless steel injectors (32 gauge, 
15 mm) connected via PE20 tubing to 1 uL syringes attached to an injector pump (Sage 
Instruments) that delivered drug at the rate of 5 uL/min. After 21 days abstinence, 
animals were tested for 4 consecutive days. On day 1, animals received an intra-mPFC 
microinjection (15 mm, 32 gauge) of mGluR5-antagonist MTEP (15 nmol/side) or saline 
and were placed in the operant boxes wherein lever-presses were recorded for 1 hr. On 
day 2, animals received an intra-mPFC microinjection of MTEP or saline (determined by 
which one was not received on day 1) and were placed in the operant chambers where 
lever-presses were recorded for 1 hr. On day 3, animals received an intra-mPFC 
microinjection of MTEP or saline followed by a systemic cocaine injection (15 mg/kg, 
i.p.). After receiving cocaine, rats were immediately placed in the chambers for 1 hr and 
lever-presses were recorded. On day 4, animals received an intra-mPFC microinjection of 
MTEP or saline (dependent on which was not administered on day 3) followed by a 
systemic cocaine injection (15 mg/kg, i.p.). Immediately after receiving the cocaine 
injection, animals were placed in the boxes for 1 hr and lever-pressing was recorded. The 
order of microinjection treatment (saline/MTEP) was counterbalanced.  
 
 
Histology and Statistics 
 
At the end of experiments, animals were deeply anesthetized with sodium 
pentothal (333 mg/kg) and transcardially perfused with 50 mL phosphate-buffered saline 
followed by 50 mL 10% paraformaldehyde. Brains were removed from the skull cavity 
and placed in formaldehyde-filled vials for at least a week. Brains were then sliced into 
100 micron sections, mounted onto gelatin-coated slides and stained with cresyl violet. 
Injector placement was then verified via light microscopy using a rat brain atlas (Paxinos 
and Watson 1997). Animals with injector placements outside of the mPFC were excluded 
from the analysis.  
 
Lever-presses recorded in MTEP and saline conditions on Day 1 and 2 (cue-
induced drug-seeking) were compared using a paired t-test. Lever-presses recorded in 
MTEP and saline conditions on Day 3 and 4 (drug-induced drug-seeking) were compared 





Cocaine hydrochloride (Sigma Chemical, St. Louis, MO) and MTEP ((3((2-
methyl-4-thiazolyl)ethynyl)pyridine hydrochloride), TOCRIS Bioscience, Ellisville, MO) 
were diluted with isotonic saline (0.9 units sodium chloride). The dose of MTEP (30 








Repeated Training Increased Cue-Induced Cocaine Self-Administration 
 
Animals were trained to lever-press for cocaine for 10 days, a time period 
sufficient to facilitate learning based on previous literature. Figure 12 shows mean 
responses (lever-presses) over the 10 training days. All animals included in the study 
increased active lever responding to the maximum number of responses (145 correct 
lever-presses) within a FR5 schedule and maintained that response level for at least the 
last 3 days of training. 
 
 
Effect of Intra-mPFC mGluR5 Blockade on Cue-Induced Drug-Seeking 
 
We hypothesized that intra-mPFC MTEP infusion would attenuate drug-seeking 
behavior, as measured by the number of responses (lever-presses), based on our previous 
data demonstrating that mPFC mGluR5 blockade prevented late expression. Figure 13 
shows the mean number of responses from animals when given intra-mPFC saline and 
MTEP. A nonsignificant trend toward an MTEP-induced reduction in responding was 
observed (t=2.133, p=0.07). 
 
 
Effect of Intra-mPFC mGluR5 Blockade on Cocaine-Induced Drug-Seeking 
 
Our previous data demonstrate a reduction in locomotor response to cocaine 
following intra-mPFC MTEP administration during late expression (Timmer and 
Steketee 2012). Figure 14 shows the mean responses of animals when given an intra-
mPFC microinjection of saline or MTEP followed by a systemic injection of cocaine (15 
mg/kg, i.p.). No significant differences were found following analysis with a paired t test. 
 
 
Differential Effect of mPFC mGluR5 Blockade on High- and Low-Responding Rats 
 
We observed that, when given intra-mPFC saline, roughly half of our animals 
exhibited a high response rate (>50 lever-presses) while the other half displayed a lower 
response rate (<50 lever-presses). On account of data suggesting intrinsic differences 
between “high-responders” and “low-responders”(Flagel et al., 2009), we segregated and 
reanalyzed our data based on these categories. Figure 15 shows mean responses of high-
responding (a) and low-responding (b) rats when given an intra-mPFC microinjection of 
saline or MTEP. MTEP significantly reduced cue-induced responding in high-responding 
(t=3.277, p<.05), but not low-responding (t=0.1628, p=0.88), animals. Figure 16 shows 
mean responses of high-responding (a) and low-responding (b) animals when given an 
intra-mPFC microinjection of saline or MTEP followed by systemic cocaine (15mg/kg, 





Figure 12. Effect of Self-Administration Training on Responses. Mean responses on 
active lever from animals (n=8). Over the 10-day training period, responses increased to 
the FR5 criterion of 145 lever-presses per session. 
  

















Figure 13. Effect of Intra-mPFC mGluR5 Activation on Cue-Induced Drug-Seeking. 
Mean responses (lever-presses) of animals (n=8) given an intra-mPFC injection of saline 
























Figure 14. Effect of Intra-mPFC mGluR5 Activation on Cocaine-Induced Drug-
Seeking. Mean responses (lever-presses) from animals (n=8) given an intra-mPFC 



















Figure 15. Effect of Intra-mPFC mGluR5 Activation on Cue-Induced Drug-Seeking 
on High- and Low-Responding Rats. Mean responses (lever-presses) of high-
responding (>50 saline, n=4) (a) and low-responding (<50 saline, n=4) (b) rats in 

































Figure 16. Effect of Intra-mPFC mGluR5 Activation on Cocaine-Induced Drug-
Seeking on High- and Low-Responding Rats. Mean responses (lever-presses) of high-
responding (>50 saline, n=5) (a) and low-responding (<50 saline, n=3) (b) rats in 
response to an intra-mPFC microinjection of saline or MTEP followed by systemic 

































The present study examined the role of mPFC mGluR5 in cue- and cocaine-
induced drug-seeking. The data demonstrate that mPFC mGluR5 blockade may attenuate 
cue-induced drug-seeking, but does not affect cocaine-induced drug seeking. Further, 
intra-mPFC mGluR5 blockade differentially affected cue-induced drug-seeking in high-
responding and low-responding animals.  
 
We previously demonstrated that intra-mPFC mGluR5 antagonism via MTEP 
significantly reduced the expression of locomotor sensitization at 21-days withdrawal. 
Thus, we were curious whether MTEP would produce any discernable decrease in drug-
seeking behavior at this time point. In the present study, intra-mPFC mGluR5 blockade 
facilitated a nonsignificant decrease in cue-induced drug-seeking. Moreover, while the 
previous MTEP-induced reduction in sensitization followed a cocaine injection, the 
present data show no effect of MTEP on drug-seeking behavior following cocaine 
administration. Several explanations for our findings are explored below. 
 
One possible reason for the decrease in the MTEP-mediated effect on drug-
seeking relative to sensitization could be the design of our self-administration 
experiments. Prior to cocaine self-administration training, it is common for animals to be 
trained to self-administer food pellets in the same chambers where they will later 
administer cocaine. Food training can result in greater acquisition rates in cocaine 
training, and possibly a more robust association between the task and a reward (Koob et 
al 2007). We did not train our animals to lever-press for food prior to cocaine training. 
While our animals displayed strong and stable acquisition rates (Figure 12), it is possible 
that their training was not as robust as it would have been had they been food-trained, 
especially after a 21-day lapse.  
 
Perhaps the most interesting aspect of our data is the discrepancy in the effect of 
MTEP on drug-seeking in high- and low-responding animals. Some of the animals in our 
study responded at relatively low levels on Days 1 and 2 (cue-induced test), and while 
responding was generally decreased in these animals following MTEP, the difference in 
responding between MTEP and saline conditions was not substantial because of the 
overall low level of response. By contrast, on Days 3 and 4 (cocaine-induced test), some 
of the previously low-responding animals drastically increased their responding 
following cocaine administration. One possible explanation, as described in the previous 
paragraph, is that task learning in some animals was not robust enough for the cue alone 
to generate the combination of drug-wanting and task- remembering necessary for a high 
response rate. However, following cocaine administration, drug-wanting dramatically 
increased and the memory of acquiring the drug was enhanced (Saunders and Robinson, 
2011), which resulted in a higher response rate. Differences between saline and MTEP 
conditions in cue-induced drug-seeking may have been more apparent in our low-
responding animals if we took measures to ensure they acquired a strong association 
between the cue and cocaine.  
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Alternatively, the difference we observed between high- and low-responding 
animals may have resulted from cue-strength variation suggested to occur in rodents 
(Meyer et al., 2012). In addicted animals, the cocaine-associated cue is thought to acquire 
an incentive salience that presumably facilitates drug-wanting and drug-seeking. 
However, recent studies suggest the cue does not become intrinsically rewarding to all 
animals and those animals that do not find the cue itself rewarding may be less vulnerable 
to addiction (Flagel et al., 2009)). It is possible that the low-responding animals in our 
study were not as motivated by the cue as the high-responders and consequently 
experienced less drug-wanting than the high-responders. If the high-responders were 
then, by this definition, more addicted than the low-responders, this indicates that mPFC 
mGluR5 antagonism is effective in reducing drug-seeking in addicted animals. The 
significant reduction in cue-induced drug-seeking following intra-mPFC mGluR5 
blockade we observed in high-responding animals supports this idea. However, the 
resultant low sample size following data segregation and the increase in responses in 
previously low-responding animals following cocaine administration precludes us from 
being certain our lack of an overall effect results from individual differences in cue 
evaluation rather than a learning impairment in low-responding animals. Additional 
experiments employing techniques to facilitate more robust learning, such as prior food 
training, should be conducted. 
 
A second reason why mPFC mGluR5 blockade may not have exerted a significant 
reduction in cue-induced drug-seeking is because the mPFC neuroadaptations that 
accompany learning to associate a cue with cocaine may be more extensive than those 
affiliated with simply receiving the drug on multiple occasions. In our previous study, we 
had proposed that MTEP reduced locomotor sensitization by decreasing the firing of 
mPFC pyramidal projection neurons, leading to a decrease in glutamatergic input to the 
NAc (Timmer and Steketee, 2012). Perhaps the mPFC plasticity that follows cue-induced 
learning serves to increase pyramidal neuronal firing to a greater extent than does the 
plasticity that accompanies a noncontingent regime, thus rendering mPFC mGluR5 
blockade less effective. If this proves true, the clinical implications of mPFC mGluR5 
modulation alone will be decreased, however, a better understanding of the relationship 
between cocaine-induced mPFC mGluR5 modifications and other alterations that may 
influence excitability could potentially pave the way for an effective pharmacological 
means of preventing relapse. 
 
Our data showed that mPFC mGluR5 antagonism did not prevent cocaine-induced 
drug-seeking. This finding is somewhat unsurprising, however, because cocaine is a more 
potent motivator than a cue alone and previous self-administration studies have failed to 
uncover an effect of a manipulation following drug administration, even when the given 
manipulation attenuated cue-induced drug-seeking (Pockros et al., 2011)(Chauvet et al., 
2009; Leri et al., 2002). What makes this finding perplexing is the stark inconsistency 
with our previous finding of an intra-mPFC MTEP-induced reduction in sensitization 
following cocaine administration. One might assume that if cocaine obliterated any effect 
of mGluR5 antagonism observed in its absence in a self-administration paradigm, we 
would be unlikely to find an effect of intra-mPFC MTEP on sensitization. However, it 
should be noted that while our previous finding showed a significant MTEP-induced 
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decrease in sensitization, sensitized animals that received MTEP still exhibited greater 
locomotion than saline controls, suggesting mPFC mGluR5 antagonism did not 
completely block the effects of cocaine. Given the abovementioned suggestion that the 
associative learning inherent in a self-administration paradigm induces an mPFC 
plasticity more effective at heightening neuronal excitability in the presence of cocaine 
and its cues, it is possible that the compounding of that plasticity with cocaine prevented 
MTEP from exerting any measurable effect on drug-seeking. Another possibility is that 
the effects of intra-mPFC mGluR5 blockade on cocaine-induced drug-seeking may have 
been too slight to measure within the self-administration paradigm. Nevertheless, our 
data strongly suggest mPFC mGluR5 antagonism does not reduce cocaine-induced drug-
seeking. 
 
Finally, the implications of this study on the role of sensitization in addiction 
research should be addressed. Despite the nonsignificant effect of intra-mPFC mGluR5 
antagonism on cue- and drug-induced drug-seeking, the observed trend towards an 
MTEP-induced reduction and significant MTEP-induced high-responder reduction in 
drug-seeking suggests that mPFC mGluR5 plays a role in addiction, which supports the 
usefulness of the simpler noncontingent method as a screening tool for addiction-relevant 
factors. As discussed above, the reasons for a lack of a significant overall effect could 
result from flaws in experimental design that affected learning, individual differences that 
influenced cue-induced motivation, or inherent differences in the plasticity induced by 
contingent and noncontingent administration techniques. A future study employing 
methods proven to maximize learning and increasing the sample size to acquire more 
high-responders might reveal a greater effect of mPFC mGlur5 antagonism on drug-
seeking, or better describe the differences between high- and low-responding animals. If 
not, the combinatorial effect of mPFC mGluR5 blockade and other mPFC manipulations 












Chapter 5. General Discussion 
 
 





Repeated intra-mPFC administration of Group I agonist DHPG induced cross-
sensitization to cocaine. This cross sensitization could be prevented via co-administration 
of mGluR5 antagonist MTEP, suggesting it was mediated by mGluR5 rather than 
mGluR1. Intra-mPFC DHPG-induced cross-sensitization could also be prevented by 
intra-VTA injections of AMPA receptor antagonist CNQX administered immediately 
prior to intra-mPFC DHPG, indicating dependence on VTA glutamatergic transmission. 
mPFC mGluR5 antagonism did not prevent the initiation of sensitization, or the early (7 
days withdrawal) expression of sensitization. However, intra-mPFC mGluR5 blockade 
did significantly attenuate late (21 days withdrawal) expression, suggesting alterations in 






Rats received daily systemic cocaine (15mg/kg i.p.) or saline injections for 4 
consecutive days. One, 7, or 21 days from the last injection, an in vivo reverse 
microdialysis experiment was conducted wherein 3 escalating concentrations (0.05 uM, 
5uM, 50uM) of Group I mGluR agonist DHPG were infused into the mPFC and samples 
were collected from the mPFC and NAc or the mPFC and VTA for later analysis of 
glutamate concentration. Results showed intra-mPFC DHPG increased mPFC glutamate 
levels at 7 days withdrawal, and NAc glutamate levels at 21 days withdrawal in 
sensitized, but not control, animals. These findings suggest mPFC mGluR5 activation 
may contribute to increased excitatory input from the mPFC to the NAc during late 
sensitization. Our data also indicate that early sensitization-induced mGluR5 alterations 
in local mPFC neurons may set the stage for later changes in NAc-projecting, mGluR5-





Animals were trained to self-administer cocaine in an operant box for 10 
consecutive days. At the conclusion of training, rats were returned to their home cages for 
21 days. Following this withdrawal period, the effect of intra-mPFC blockade via 
mGluR5 antagonist MTEP on cue- and cocaine-induced drug-seeking was assessed. We 
observed a nonsignificant trend towards decreased cue-induced drug-seeking following 





          Cocaine addicts experience a lifelong struggle to control drug-seeking behavior and 
many relapse, even after years of withdrawal. Therefore, the overarching goal of 
addiction research is to understand the mechanisms that contribute to relapse. Imaging 
studies in cocaine addicts have revealed increased mPFC activity in response to cocaine 
and related cues, and decreased mPFC activity in response to other stimuli (Goldstein and 
Volkow, 2011). Similarly, non-human studies have demonstrated increased cocaine-
induced excitability of mPFC pyramidal neurons in sensitized animals, a phenomenon 
that might ultimately result in increased excitatory input to reward-associated brain 
regions, such as the NAc. Furthermore, given the role of the mPFC in excutive functions, 
increased mPFC responsiveness to cocaine and its cues at the expense of non-drug 
information may contribute to the seemingly irrational and sometimes self-destructive 
decisions an addict will make to obtain cocaine. Consequently, an understanding of the 
processes that give rise to the mPFC excitability that follows repeated cocaine exposure 
may open new doors for lessening the risk of relapse. 
 
The data from the present studies suggest mPFC mGluR5 contributes to the 
regulation of the excitability of mPFC projections to the NAc during late, but not early, 
sensitization. We first showed that intra-mPFC blockade significantly attenuated the 
locomotor response to cocaine in sensitized rats at 21, but not 7, days withdrawal. Then, 
we observed increased NAc glutamate levels following mPFC mGluR5 activation at 21 
days withdrawal in sensitized animals. Finally, we noted a nonsignificant trend towards a 
reduction in cue-induced drug-seeking following intra-mPFC mGluR5 antagonism at 21 
days withdrawal.  
  
The key finding from our first set of experiments (chapter 2) was the reduction in 
late expression following mPFC mGluR5 blockade, however, the failure of intra-mPFC 
mGluR5 blockade to prevent early expression was somewhat puzzling. One explanation 
we offered at the time was that cocaine-induced mPFC glutamate levels were too high to 
reveal an effect of mGluR5 blockade during early expression. A second possibility we 
proposed was that, due to alterations in mGluR5 itself or other late-sensitization-
associated cellular changes, mGluR5 activation was more influential over mPFC 
neuronal output during late sensitization. Results from our second set of experiments 
(chapter 3) suggest the latter explanation may be more accurate because we observed a 
glutamate increase in the NAc following mPFC mGluR5 stimulation during late, but not 
early, expression. Future studies could explore potential changes in mGluR5-bearing 
NAc projections within the mPFC from early to late expression. 
  
An interesting question our findings raise is whether and how early changes in the 
mPFC glutamate system give rise to later alterations in communication between the 
mPFC and other regions, such as the NAc. We showed that mPFC mGluR5 activation 
increased mPFC glutamate levels at 7 days withdrawal in sensitized animals, an effect 
that was not present during late sensitization. As previously discussed, repeated cocaine 
exposure may induce alterations in mGluR5-bearing local mPFC projections earlier than 
in neurons that project to other brain regions. As is the case with mGluR5 alterations that 
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are associated with late sensitization, we do not know whether mGluR5 is altered in local 
projections during early sensitization or if other cellular properties are changed in a way 
that makes mGluR5 activation more likely to increase firing. Nonetheless, it is possible 
that early mGluR5-associated changes could represent a critical step in more permanent 
mGluR5-affiliated alterations in mPFC projection neurons. Differences in mGluR5 
presence and activity in local and NAc-projecting mPFC neurons could be explored in 
the future, as could related alterations that may potentially affect the influence of 
mGluR5 over neuronal excitability.  
  
The significant decrease in late expression and the nonsignificant but notable 
reduction in cue-induced drug-seeking observed in animals following intra-mPFC 
mGluR5 blockade suggests mPFC mGluR5 is involved with processes that mediate long-
term cocaine addiction. While we did not observe an effect of mPFC mGluR5 
antagonism on cocaine-induced drug-seeking, our data still suggest that mPFC mGluR5 
antagonism reduces the influence of cocaine and related cues on addictive behavior. That 
said, as discussed earlier, further studies employing the self-administration paradigm 
should be conducted in a manner than maximizes task acquisition and contains a sample 
size sufficient to yield a suitable number of high-responding animals. Such an experiment 
will shed light on whether the failure of mPFC mGluR5 antagonism to significantly 
reduce cue-induced drug-seeking resulted from experimental design, individual 
differences or the lack of a substantial role of mGluR5 in drug-seeking.  
  
An ancillary objective of our self-administration experiments was to assess the 
congruency of findings obtained using a contingent and a noncontingent method. As 
previously discussed, the discrepancy in drug administration that exists between the 
noncontingent method and the process addicts undergo while becoming dependent on 
cocaine has called into question the usefulness of the noncontingent method in addiction 
research. Since our data collected using a contingent method showed a nonsignificant 
reduction in cue-induced drug-seeking following intra-mPFC mGluR5 antagonism that 
may be more pronounced under different experimental conditions, and our data obtained 
using a noncontingent methods showed an mPFC mGluR5-mediated reduction in late 
expression, a substantial degree of similarity appears to exist. Given the simplicity and 
straightforwardness of the noncontingent method, its employment as a screening 
technique performed prior to more involved experiments seems suitable.  
  
Taken together, our experiments are the first to explore the role of mPFC mGluR5 
in cocaine addiction and our data suggest this receptor may contribute to the enhanced 
excitability of sensitized mPFC pyramidal cells. Given that the effects of intra-mPFC 
mGluR5 manipulations were observable during late sensitization, alterations in mPFC 
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